CA2123128A1 - Method for making a prolineboronate ester - Google Patents
Method for making a prolineboronate esterInfo
- Publication number
- CA2123128A1 CA2123128A1 CA002123128A CA2123128A CA2123128A1 CA 2123128 A1 CA2123128 A1 CA 2123128A1 CA 002123128 A CA002123128 A CA 002123128A CA 2123128 A CA2123128 A CA 2123128A CA 2123128 A1 CA2123128 A1 CA 2123128A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- pinanediol
- yield
- ester
- boronate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 81
- 150000002148 esters Chemical class 0.000 title claims abstract description 22
- -1 N-protected pyrrole Chemical class 0.000 claims abstract description 46
- MOILFCKRQFQVFS-BDNRQGISSA-N (1r,3s,4r,5r)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol Chemical compound C1[C@@H]2C(C)(C)[C@H]1C[C@H](O)[C@@]2(O)C MOILFCKRQFQVFS-BDNRQGISSA-N 0.000 claims abstract description 43
- 125000006239 protecting group Chemical group 0.000 claims abstract description 32
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000002253 acid Substances 0.000 claims abstract description 27
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims abstract description 27
- 150000002009 diols Chemical class 0.000 claims abstract description 16
- 150000001413 amino acids Chemical class 0.000 claims abstract description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 11
- 125000004185 ester group Chemical group 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 69
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 20
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 claims description 16
- 125000005647 linker group Chemical group 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 14
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 10
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical group [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000003729 cation exchange resin Substances 0.000 claims description 7
- 239000007800 oxidant agent Substances 0.000 claims description 7
- AJSTXXYNEIHPMD-UHFFFAOYSA-N triethyl borate Chemical compound CCOB(OCC)OCC AJSTXXYNEIHPMD-UHFFFAOYSA-N 0.000 claims description 7
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical group COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 5
- IHPDTPWNFBQHEB-UHFFFAOYSA-N hydrobenzoin Chemical compound C=1C=CC=CC=1C(O)C(O)C1=CC=CC=C1 IHPDTPWNFBQHEB-UHFFFAOYSA-N 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- ZWGMJLNXIVRFRJ-UHFFFAOYSA-N [1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrol-2-yl]boronic acid Chemical compound CC(C)(C)OC(=O)N1C=CC=C1B(O)O ZWGMJLNXIVRFRJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052720 vanadium Inorganic materials 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- MOILFCKRQFQVFS-VUMZSGCYSA-N (3r,4s)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol Chemical compound C1C2C(C)(C)C1C[C@@H](O)[C@]2(O)C MOILFCKRQFQVFS-VUMZSGCYSA-N 0.000 claims 5
- 230000001681 protective effect Effects 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 3
- 150000004653 carbonic acids Chemical class 0.000 claims 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- MOILFCKRQFQVFS-AZQAYCESSA-N (1s,3s,4r,5s)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol Chemical compound C1[C@H]2C(C)(C)[C@@H]1C[C@H](O)[C@@]2(O)C MOILFCKRQFQVFS-AZQAYCESSA-N 0.000 claims 2
- 150000000180 1,2-diols Chemical class 0.000 claims 2
- OVVMNBVQOPZMPY-NTEAFONJSA-N 149716-73-4 Chemical compound Cl.O([C@]1(C)[C@@H]2C[C@H](C[C@@H]1O1)C2(C)C)B1[C@H]1CCCN1 OVVMNBVQOPZMPY-NTEAFONJSA-N 0.000 claims 2
- 239000011260 aqueous acid Substances 0.000 claims 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 10
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract description 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 229910052796 boron Inorganic materials 0.000 abstract description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 4
- 125000005620 boronic acid group Chemical group 0.000 abstract description 4
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 102000035195 Peptidases Human genes 0.000 abstract description 3
- 108091005804 Peptidases Proteins 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- WADSQZHEAXPENM-UHFFFAOYSA-N 1h-pyrrol-2-ylboronic acid Chemical compound OB(O)C1=CC=CN1 WADSQZHEAXPENM-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004365 Protease Substances 0.000 abstract description 2
- 150000001735 carboxylic acids Chemical class 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- HISWWEXBLOFKSH-UHFFFAOYSA-N [Li]C1CCCN1 Chemical compound [Li]C1CCCN1 HISWWEXBLOFKSH-UHFFFAOYSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 58
- 239000000243 solution Substances 0.000 description 50
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 48
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 38
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 31
- 239000007787 solid Substances 0.000 description 27
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 238000005481 NMR spectroscopy Methods 0.000 description 23
- 239000000203 mixture Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 101150041968 CDC13 gene Proteins 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 150000001642 boronic acid derivatives Chemical class 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000006138 lithiation reaction Methods 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 3
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- CQMHKCYAPOVFMJ-UHFFFAOYSA-N phenylboronic acid 2,6,6-trimethylbicyclo[3.1.1]heptane-1,2-diol Chemical compound OB(O)C1=CC=CC=C1.C1C2(O)C(C)(C)C1CCC2(O)C CQMHKCYAPOVFMJ-UHFFFAOYSA-N 0.000 description 2
- 229940117953 phenylisothiocyanate Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- YAXWOADCWUUUNX-UHFFFAOYSA-N 1,2,2,3-tetramethylpiperidine Chemical compound CC1CCCN(C)C1(C)C YAXWOADCWUUUNX-UHFFFAOYSA-N 0.000 description 1
- AWNXKZVIZARMME-UHFFFAOYSA-N 1-[[5-[2-[(2-chloropyridin-4-yl)amino]pyrimidin-4-yl]-4-(cyclopropylmethyl)pyrimidin-2-yl]amino]-2-methylpropan-2-ol Chemical compound N=1C(NCC(C)(O)C)=NC=C(C=2N=C(NC=3C=C(Cl)N=CC=3)N=CC=2)C=1CC1CC1 AWNXKZVIZARMME-UHFFFAOYSA-N 0.000 description 1
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 238000006219 Matteson homologation reaction Methods 0.000 description 1
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical class OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 1
- CBQJSKKFNMDLON-JTQLQIEISA-N N-acetyl-L-phenylalanine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-N 0.000 description 1
- IHYJTAOFMMMOPX-LURJTMIESA-N N-acetyl-L-valine Chemical compound CC(C)[C@@H](C(O)=O)NC(C)=O IHYJTAOFMMMOPX-LURJTMIESA-N 0.000 description 1
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical class NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- IBFLWIOFZGYDFZ-WCCKRBBISA-N OBO.OC(=O)[C@@H]1CCCN1 Chemical compound OBO.OC(=O)[C@@H]1CCCN1 IBFLWIOFZGYDFZ-WCCKRBBISA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229960000669 acetylleucine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 125000005621 boronate group Chemical group 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- PMPYSSMGWFNAAQ-UHFFFAOYSA-N dichloromethane;n,n-diethylethanamine Chemical compound ClCCl.CCN(CC)CC PMPYSSMGWFNAAQ-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 238000011905 homologation Methods 0.000 description 1
- 238000006197 hydroboration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical class [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- ANYSGBYRTLOUPO-UHFFFAOYSA-N lithium tetramethylpiperidide Chemical compound [Li]N1C(C)(C)CCCC1(C)C ANYSGBYRTLOUPO-UHFFFAOYSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- VQEVKEKJZVEGPH-UHFFFAOYSA-N lithium;chloromethane Chemical compound [Li+].Cl[CH2-] VQEVKEKJZVEGPH-UHFFFAOYSA-N 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- AGVMWTWBONEXNA-UHFFFAOYSA-N pyrrolidin-2-ylboronic acid;hydrochloride Chemical compound Cl.OB(O)C1CCCN1 AGVMWTWBONEXNA-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IZPYBIJFRFWRPR-UHFFFAOYSA-N tert-butyl pyrrole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=CC=C1 IZPYBIJFRFWRPR-UHFFFAOYSA-N 0.000 description 1
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method for the preparation of esters of prolineboronic acid is described. An N-protected pyrrole (I) is lithiated at the 2-position. The lithiated species (II) is reacted with trialkylborate, to yield a protected pyrrole-2-boronic acid (III). This is reduced to form a protected prolineboronic acid (IV), which, in turn, is reacted with a diol to yield an ester (VI). With the boronic acid moiety protected by the ester group, the protecting group on the nitrogen is removed, yielding the desired prolineboronic acid ester (VII). In an alternative synthesis, a protected pyrrolidine (VIII) is lithiated at the 2-position to yield a protected 2-lithio-pyrrolidine (IX). This is reacted with trialkylborate to yield the intermediate IV. The prolineboronic acid esters so produced have a chiral center to the boron atom. Also disclosed are methods for resolving enantiomers. The final products can be coupled to activated carboxylic acids, to yield peptides having a prolineboronic acid ester, instead of an amino acid, at the C-terminus.
These boronic acid peptide analogs are useful for inhibiting biologically important proteases. Several methods for removing pinanediol from pinanediol boronate esters are also disclosed.
These boronic acid peptide analogs are useful for inhibiting biologically important proteases. Several methods for removing pinanediol from pinanediol boronate esters are also disclosed.
Description
WO 93/10127 PCI`/US92/09845 ETHOD_FOR MAKING A PROLINEBORO~AFL ESTER
Field of the Invention The invention relates to a method for making optically active prolineboronate esters. These are useful as intermediates in the production of peptides which incorporate prolineboronic acid instead of proline.
These peptides, in turn, are useful for inhibiting various biologically important proteases.
Backqround of the Invention Interest in boronic acid analogs of ~-amino acids, as well as peptid~s incorporating a boronic acid analog of an ~-amino acid instead of the C-terminal residue, has been generated by reports that these compounds are efficient inhibitors of many serine proteases. See, for example, Matteson et al. ~J. Am.
Chem. Soc. 103, 5241 ~1981)], Kettner et al. ~J.
Biol. Chem. 259, 15106 (1984)]; and, Kinder et al. ~-~J. Med. Chem. 27, 1919 (1985)~. `
Several workers, including Koehler et al.
[Biochemistry, 10, 2477 (1971)] and Rawn et al.
[Biochemistry, 13, 3124 (1974~] have hypothesized that the empty p-orbital centered at boron in these compounds interacts with an active-site hydroxyl group of the enzyme, to form a tetrahedral adduct that mimics the transition state of enzymatic hydrolysis.
It is thought that the boronic acid analog binds more tightly to the enzyme than does the substrate itself, thereby inhibiting enzymatic action upon the substrate.
WO93/10127 PCT/US92~09~5 .
The boronic acid analogs of ~-amino acids and peptides incorporating them are currently of use in research because they are able to shed light on the biological functions of the enzymes they inhi~it.
Further, as explained below, they are also therapeutically useful.
Peptides which incorporate the ~-aminoboronic acid analog of proline (BoroPro) at the C-terminus are of' special interest because they have been shown to be potent inhibitors of certain post-proline cleaving enzymes. For example, Bachovchin et al. [J. Biol.
Chem. 265, 3738 (1990)] have reported that such peptides are inhibitors of IgA proteinases from certain bacteria. These enzymes are strongly implicated in bacterial virulence. Flentke et al.
[Proc. Natl. Acad. Sci. USA 88, 1556 (1991)] have reported that such peptides inhibit dipeptidyl peptidase IV (DP-IV), which in turn causes inhibition -of antigen-induced proliferation and IL-2 production in T-cells. The latter effects are known to result in suppression of the immune response. Suppression of the immune response is, in turn, useful in the treatment of, for example, organ transplant rejection, graft versus host disease, and various autoimmune diseases.
Previous synthetic routes to ~-amino boronic acids rely on the procedure published in 1981 by Matteson et al., supra, which follows the sequence of hydroboration, (asymmetric) homologation with chloromethyllithium, and aminolysis. Matteson et al.
[Organometallics 3, 1284 (1984)] have described the use of this technique to synthesize the boronic acid WO93/10127 PCT/US92/09~5 ` .:
212~128 analogues of N-acetylalanine, N-acetylvaline, N~acetylleucine, and N-acetylphenylalanine; some of -these have been obtained with good ~9 diastereomeric ratios.
The application of the Matteson procedure to the synthesis of BoroPro has been demonstrated by Bachovachin, supra, and Flentke, supra, but the extensive modifications required for the construction of the pyrrolidine ring render it unappealing.
Furthermore, conditions for the preparation of a single enantiomer of BoroPro, either by asymmetric synthesis or by resolution, have not been reported.
,.
Ef~orts to explore further the biochemistry of the post-proline clea~ing enzymes, particularly DP-IV, and the possible therapeutic uses of BoroPro-based enzyme inhi~itors, have been hampered by the lack of an efficient route to prolineboronic acid.
~ , The need for a better source of BoroPro led us to explore alternate routes to this compound, especially the compound in its optically active form, and has resulted in the present invention.
'~''.
~ SummarV of the Invention , .
A first broad aspect of the present invention comprises three closely related methods for the synthesis of prolineboronic acid esters. Two of these syntheses commence from pyrrole. The third commences from pyrrolidine. Included within the scope of this first aspect of the invention are certain novel intermediates. Prolineboronic acid has a chiral WO93/10127 PC~/US92~09~5 21~3128 center ~ to the boron atom. A second broad aspect of the invention comprises a method for resolving the enantiomers of prolineboronic acid, if desired.
According to this method, the prolineboronic ester is formed through reaction with a chiral alcohol, with the use of pinanediol being particularly preferred.
Resolution of enantiomers is facilitated by separating the diastereomPric mixture resulting from the introduction of additional chiral centers. The ' resulting prolineboronic acid esters can be easily coupled to activated carboxylic acid groups, such as are typically used in peptide synthesis, to yield peptides having a prolineboronic acid ester, instead of an amino acid, at the C-terminus. The ester protecting group can be removed to yield the free boronic acid peptide. When the est2r protecting group is pinanediol, it is not easily removed by known per se techniques. A third aspect of the invention comprises several methods for removing the pinanediol protecting group.
Br ef Descriptlon_of the Drawinq Figure l illustrates a reaction scheme which is a preferred embodiment of the invention.
Detailed Description of the Invention A first synthesis according to the invention commences with pyrrole, which is reacted with an activated derivative of carbonic acid, in order to protect the nitrogen atom with a group of the formula -COOR, wherein R is Cl 6alkyl, C3 6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more Cl 6 alkyl groups, or trimethylsilylethyl, in order to yield a compound of the formula I
WQ~3~10127 PCT/US92/09~5 , 212312~
R0 ~ (I) In the preferred protecting groups, R is tert-butyl, benzyl, trimethylsilylethyl, phenyl, methyl or ethyl.
The most preferred protecting group is tert-butyloxycarbonyl, or Boc. The protecting group is applied using well known techniques. A specific synthesis for 1-Boc-pyrrole has been described by Grehn et al. [Angew. Chem. Int. Ed. Engl. 23, 296 (1~84)~.
The compound of formula I is next treated with a lithiating agent to yield a compound of the formula II
N Li RO~o (II) ' wherein R is defined as before.
Lithiation of the compound of formula I can ~e accomplished by treatment with lithium tetramethylpiperidide in a known per se manner; such as that described by Hasan et al. ~J. Org. Chem. 46, 157 (1981)], or with other hindered lithium amides such as lithium diisopropyl amide or lithium dicyclohexylamide, or with n-butyl lithium in the WO93~10127 PCT/US92/09~5 ,.. ~, :
21~3128 6 presence of tetramethyl ethylenediamine. This reaction is conveniently carried out in an inert solvent, preferably an ether such as THF, diethyl ~.
ether, dimethoxyethane, or methyl t-butyl ether at a temperature between -78C and -40C. Alternatively, pyrrole can be brominated at the 2-position, in a ;:
known per se manner, such as that described by Chen et al., [Org. Syn., 70, l5l (l99l)], and the resulting product can be protected and then li.thiated, using other less expensive lithiating agents, such as n-butyl lithium, using known per se techniques.
.
The intermediate of formula II, which is not isolated, is next reacted with a trialkyl borate wherein each al~yl group may be straight, branched or cyclic and contains l to 6 carbon atoms, preferably trimethyl or triethyl borate, followed by acid-catalyzed hydrolysis, using a weak acid such as citric or acetic acid, or potassium hydrogen sulfate, in order to yield a protected pyrrole-2-boronic acid of formula III
~ \ (III) L OH
~: RO O
wherein R is defined as before.
The intermediate of formula III is next reduced, using catalytic hydrogenation, to form a protected prolineboronic acid of the formula IV
212~128 B/ H
~ O~
wherein R is defined as before.
1~
The catalytic hydrogenation of the intermediate of formula III may be carried out in an organic solvent, such as ethyl acetate or tetrahydrofuran, using a catalyst such as 5~ platinum on carbon, platinum oxide, rhodium on carbon, rhodium on alumina, palladium on carbon, or Raney nickel, either at atmospheric pressure, or at about 50 psi.
An alternative synthesis of the boronic acid of formula IV uses pyrrolidine which is treated with a suitable acylating agent, to yield a protected compound of the formula VIII
WO93/10~7 P~T/US~2/0984~
2123~8 8 ¦ (VIII) R o/~o wherein R is defined as before.
~ , The protecting group is chosen to allow activation of the pyrrolidine to lithiation adjacent to the nitrogen, and it should contain a bulky moiety which hinders attack on the carbonyl by the lithiating agent. It is preferred to use a carbamoyl protecting group of the formula -COOR, for example, groups wherein R is tert-butoxy or 2,4,6-tri-tert-butylphenoxy. However, certain acyl or aroyl groups can also be used, for example tert-butylcarbonyl or triphenylmethylcarbonyl. Other suitable activating :;
groups are outlined in Beak et al., [Chem. Rev., 84, -471-523, (1984)]. The most preferred protecting group is tert-butyloxycarbonyl, or Boc. The protecting group may be applied to pyrrolidine by well known techniques.
The compound of formula VIII is next treated with a lithiating agent to yield a compound of the formula IX
WO93/1~127 PCT/US92/0~5 2123128 :~
~ (IX) RQ"~0 wherein R is defined as before.
Lithiation of the compound of formula VIII can be accomplished by treatment with sec-butyl lithium and tetramethyl ethylenediamine in a known per se manner, such as that described by Beak et al. [Tet. Lett.
30, 1197 ~1989)]. This reaction is conveniently arried out in an inert organic solvent, preferably an ether such as diethyl ether, methyl tert-butyl ether or THF at a temperature between about -78C and 0C, ~-~
preferably -78~ to 40C. Lithiation may be achieved with a reactive alkyl lithium such as sec-butyl lithium or tert-butyl lithium, pr~ferably in the presence of a coordinating additive such as tetramethyl ethylenediamine, hexamethyl phosphoramide ~-or N,N'-dimethylpropyleneurea ~DMPU).
.
The intermediate of formula IX, which is not isolated, is next rea~ted with a trialkyl borate wherein each alkyl group may be straight, branched or cyclic and contains 1 to 6 carbon atoms, preferably trimethyllor triethyl borate, followed by hydrolysis with water-and extraction into aqueous alkali such as sodium hydroxide or potassium hydroxide to aid purification.
Acidification of the alkali solution to about pH 3 and extraction yields the protected prolineboronic acid of formula IV.
W~ g3J10127 Pcr/uss2/~s~4s -' 10 ~1~31~.8 In order to form a boronic acid ester, the free boronic acid intermediate of formula IV, is next esterified by reaction with a diol of the formula V, HO-X-OH (V) wherein X is a linking group, to yield a compound of' the formula VI
~N~ B~
\O ~ ~VI) RO'-~'~
wherein X is the same linking group mentioned above and R is defined as before. The ester group thus formed is intended to function only as a removable protecting group. The structures, syntheses, and methods for attachment and removal of such ester protecting groups are generally known in the chemical art. Accordingly, those skilled in the chemical art will appreciate that the structure of the linking group X is not critical. The linking group X can be, by way of non-limiting examples, a saturated 2- to 3-membered hydrocarbon chain; a saturated 2- to 3-membered hydrocarbon chain which constitutes part of a C5 12 carbocyclic system which may optionally contain unsaturations or ring fusions; a 2- to 3-membered hydrocarbon chain which constitutes part of an aromatic ring system; or, a group of the formula WO93~10127 PCT/US92/~9~5 "
11 .
Field of the Invention The invention relates to a method for making optically active prolineboronate esters. These are useful as intermediates in the production of peptides which incorporate prolineboronic acid instead of proline.
These peptides, in turn, are useful for inhibiting various biologically important proteases.
Backqround of the Invention Interest in boronic acid analogs of ~-amino acids, as well as peptid~s incorporating a boronic acid analog of an ~-amino acid instead of the C-terminal residue, has been generated by reports that these compounds are efficient inhibitors of many serine proteases. See, for example, Matteson et al. ~J. Am.
Chem. Soc. 103, 5241 ~1981)], Kettner et al. ~J.
Biol. Chem. 259, 15106 (1984)]; and, Kinder et al. ~-~J. Med. Chem. 27, 1919 (1985)~. `
Several workers, including Koehler et al.
[Biochemistry, 10, 2477 (1971)] and Rawn et al.
[Biochemistry, 13, 3124 (1974~] have hypothesized that the empty p-orbital centered at boron in these compounds interacts with an active-site hydroxyl group of the enzyme, to form a tetrahedral adduct that mimics the transition state of enzymatic hydrolysis.
It is thought that the boronic acid analog binds more tightly to the enzyme than does the substrate itself, thereby inhibiting enzymatic action upon the substrate.
WO93/10127 PCT/US92~09~5 .
The boronic acid analogs of ~-amino acids and peptides incorporating them are currently of use in research because they are able to shed light on the biological functions of the enzymes they inhi~it.
Further, as explained below, they are also therapeutically useful.
Peptides which incorporate the ~-aminoboronic acid analog of proline (BoroPro) at the C-terminus are of' special interest because they have been shown to be potent inhibitors of certain post-proline cleaving enzymes. For example, Bachovchin et al. [J. Biol.
Chem. 265, 3738 (1990)] have reported that such peptides are inhibitors of IgA proteinases from certain bacteria. These enzymes are strongly implicated in bacterial virulence. Flentke et al.
[Proc. Natl. Acad. Sci. USA 88, 1556 (1991)] have reported that such peptides inhibit dipeptidyl peptidase IV (DP-IV), which in turn causes inhibition -of antigen-induced proliferation and IL-2 production in T-cells. The latter effects are known to result in suppression of the immune response. Suppression of the immune response is, in turn, useful in the treatment of, for example, organ transplant rejection, graft versus host disease, and various autoimmune diseases.
Previous synthetic routes to ~-amino boronic acids rely on the procedure published in 1981 by Matteson et al., supra, which follows the sequence of hydroboration, (asymmetric) homologation with chloromethyllithium, and aminolysis. Matteson et al.
[Organometallics 3, 1284 (1984)] have described the use of this technique to synthesize the boronic acid WO93/10127 PCT/US92/09~5 ` .:
212~128 analogues of N-acetylalanine, N-acetylvaline, N~acetylleucine, and N-acetylphenylalanine; some of -these have been obtained with good ~9 diastereomeric ratios.
The application of the Matteson procedure to the synthesis of BoroPro has been demonstrated by Bachovachin, supra, and Flentke, supra, but the extensive modifications required for the construction of the pyrrolidine ring render it unappealing.
Furthermore, conditions for the preparation of a single enantiomer of BoroPro, either by asymmetric synthesis or by resolution, have not been reported.
,.
Ef~orts to explore further the biochemistry of the post-proline clea~ing enzymes, particularly DP-IV, and the possible therapeutic uses of BoroPro-based enzyme inhi~itors, have been hampered by the lack of an efficient route to prolineboronic acid.
~ , The need for a better source of BoroPro led us to explore alternate routes to this compound, especially the compound in its optically active form, and has resulted in the present invention.
'~''.
~ SummarV of the Invention , .
A first broad aspect of the present invention comprises three closely related methods for the synthesis of prolineboronic acid esters. Two of these syntheses commence from pyrrole. The third commences from pyrrolidine. Included within the scope of this first aspect of the invention are certain novel intermediates. Prolineboronic acid has a chiral WO93/10127 PC~/US92~09~5 21~3128 center ~ to the boron atom. A second broad aspect of the invention comprises a method for resolving the enantiomers of prolineboronic acid, if desired.
According to this method, the prolineboronic ester is formed through reaction with a chiral alcohol, with the use of pinanediol being particularly preferred.
Resolution of enantiomers is facilitated by separating the diastereomPric mixture resulting from the introduction of additional chiral centers. The ' resulting prolineboronic acid esters can be easily coupled to activated carboxylic acid groups, such as are typically used in peptide synthesis, to yield peptides having a prolineboronic acid ester, instead of an amino acid, at the C-terminus. The ester protecting group can be removed to yield the free boronic acid peptide. When the est2r protecting group is pinanediol, it is not easily removed by known per se techniques. A third aspect of the invention comprises several methods for removing the pinanediol protecting group.
Br ef Descriptlon_of the Drawinq Figure l illustrates a reaction scheme which is a preferred embodiment of the invention.
Detailed Description of the Invention A first synthesis according to the invention commences with pyrrole, which is reacted with an activated derivative of carbonic acid, in order to protect the nitrogen atom with a group of the formula -COOR, wherein R is Cl 6alkyl, C3 6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more Cl 6 alkyl groups, or trimethylsilylethyl, in order to yield a compound of the formula I
WQ~3~10127 PCT/US92/09~5 , 212312~
R0 ~ (I) In the preferred protecting groups, R is tert-butyl, benzyl, trimethylsilylethyl, phenyl, methyl or ethyl.
The most preferred protecting group is tert-butyloxycarbonyl, or Boc. The protecting group is applied using well known techniques. A specific synthesis for 1-Boc-pyrrole has been described by Grehn et al. [Angew. Chem. Int. Ed. Engl. 23, 296 (1~84)~.
The compound of formula I is next treated with a lithiating agent to yield a compound of the formula II
N Li RO~o (II) ' wherein R is defined as before.
Lithiation of the compound of formula I can ~e accomplished by treatment with lithium tetramethylpiperidide in a known per se manner; such as that described by Hasan et al. ~J. Org. Chem. 46, 157 (1981)], or with other hindered lithium amides such as lithium diisopropyl amide or lithium dicyclohexylamide, or with n-butyl lithium in the WO93~10127 PCT/US92/09~5 ,.. ~, :
21~3128 6 presence of tetramethyl ethylenediamine. This reaction is conveniently carried out in an inert solvent, preferably an ether such as THF, diethyl ~.
ether, dimethoxyethane, or methyl t-butyl ether at a temperature between -78C and -40C. Alternatively, pyrrole can be brominated at the 2-position, in a ;:
known per se manner, such as that described by Chen et al., [Org. Syn., 70, l5l (l99l)], and the resulting product can be protected and then li.thiated, using other less expensive lithiating agents, such as n-butyl lithium, using known per se techniques.
.
The intermediate of formula II, which is not isolated, is next reacted with a trialkyl borate wherein each al~yl group may be straight, branched or cyclic and contains l to 6 carbon atoms, preferably trimethyl or triethyl borate, followed by acid-catalyzed hydrolysis, using a weak acid such as citric or acetic acid, or potassium hydrogen sulfate, in order to yield a protected pyrrole-2-boronic acid of formula III
~ \ (III) L OH
~: RO O
wherein R is defined as before.
The intermediate of formula III is next reduced, using catalytic hydrogenation, to form a protected prolineboronic acid of the formula IV
212~128 B/ H
~ O~
wherein R is defined as before.
1~
The catalytic hydrogenation of the intermediate of formula III may be carried out in an organic solvent, such as ethyl acetate or tetrahydrofuran, using a catalyst such as 5~ platinum on carbon, platinum oxide, rhodium on carbon, rhodium on alumina, palladium on carbon, or Raney nickel, either at atmospheric pressure, or at about 50 psi.
An alternative synthesis of the boronic acid of formula IV uses pyrrolidine which is treated with a suitable acylating agent, to yield a protected compound of the formula VIII
WO93/10~7 P~T/US~2/0984~
2123~8 8 ¦ (VIII) R o/~o wherein R is defined as before.
~ , The protecting group is chosen to allow activation of the pyrrolidine to lithiation adjacent to the nitrogen, and it should contain a bulky moiety which hinders attack on the carbonyl by the lithiating agent. It is preferred to use a carbamoyl protecting group of the formula -COOR, for example, groups wherein R is tert-butoxy or 2,4,6-tri-tert-butylphenoxy. However, certain acyl or aroyl groups can also be used, for example tert-butylcarbonyl or triphenylmethylcarbonyl. Other suitable activating :;
groups are outlined in Beak et al., [Chem. Rev., 84, -471-523, (1984)]. The most preferred protecting group is tert-butyloxycarbonyl, or Boc. The protecting group may be applied to pyrrolidine by well known techniques.
The compound of formula VIII is next treated with a lithiating agent to yield a compound of the formula IX
WO93/1~127 PCT/US92/0~5 2123128 :~
~ (IX) RQ"~0 wherein R is defined as before.
Lithiation of the compound of formula VIII can be accomplished by treatment with sec-butyl lithium and tetramethyl ethylenediamine in a known per se manner, such as that described by Beak et al. [Tet. Lett.
30, 1197 ~1989)]. This reaction is conveniently arried out in an inert organic solvent, preferably an ether such as diethyl ether, methyl tert-butyl ether or THF at a temperature between about -78C and 0C, ~-~
preferably -78~ to 40C. Lithiation may be achieved with a reactive alkyl lithium such as sec-butyl lithium or tert-butyl lithium, pr~ferably in the presence of a coordinating additive such as tetramethyl ethylenediamine, hexamethyl phosphoramide ~-or N,N'-dimethylpropyleneurea ~DMPU).
.
The intermediate of formula IX, which is not isolated, is next rea~ted with a trialkyl borate wherein each alkyl group may be straight, branched or cyclic and contains 1 to 6 carbon atoms, preferably trimethyllor triethyl borate, followed by hydrolysis with water-and extraction into aqueous alkali such as sodium hydroxide or potassium hydroxide to aid purification.
Acidification of the alkali solution to about pH 3 and extraction yields the protected prolineboronic acid of formula IV.
W~ g3J10127 Pcr/uss2/~s~4s -' 10 ~1~31~.8 In order to form a boronic acid ester, the free boronic acid intermediate of formula IV, is next esterified by reaction with a diol of the formula V, HO-X-OH (V) wherein X is a linking group, to yield a compound of' the formula VI
~N~ B~
\O ~ ~VI) RO'-~'~
wherein X is the same linking group mentioned above and R is defined as before. The ester group thus formed is intended to function only as a removable protecting group. The structures, syntheses, and methods for attachment and removal of such ester protecting groups are generally known in the chemical art. Accordingly, those skilled in the chemical art will appreciate that the structure of the linking group X is not critical. The linking group X can be, by way of non-limiting examples, a saturated 2- to 3-membered hydrocarbon chain; a saturated 2- to 3-membered hydrocarbon chain which constitutes part of a C5 12 carbocyclic system which may optionally contain unsaturations or ring fusions; a 2- to 3-membered hydrocarbon chain which constitutes part of an aromatic ring system; or, a group of the formula WO93~10127 PCT/US92/~9~5 "
11 .
2 t23~ 28 --(CH2)n-NH-(CH2)m~, wherein n and m are each 2 or 3; wherein such groups may be unsubstituted or substituted by one or more C1 3alkyl or phenyl ~
groups. ~.
Accordingly, suitable diols of formula V are, for example, ethylene glycol, pinacol, catechol, pinanediol, butan-2,3-diol, 2,2-dimethyl propan 1,3-diol, diethanolamine and 1,2-diphenylethan-1,2-diol.
With the boronic acid moiety protected by the ester .
group, the protecting group on the nitrogen is next removed using known per se techniques, such as those described by Greene in "Protective Groups in Organic Synthesis" (J. Wiley & Sons, 1981), to yield the hydrochloride of the desired prolineboronic acid ester of the formula VII.
:: A
\ (VII) H 0'' ; ~:
, For example, when the protecting group is Boc, it may be easily removed with dry hydrogen chloride in ethyl acetate.
It is preferred to perform the esterification of the ;~
compound of formula IV with a chiral, non-racemic diol such as (lS,2S,3R,5S~ )-pinanediol, 1,2-diphenylethan-1,2-diol or butan-2,3,-diol, because :
so doing introduces additional chiral centers into the molecule. This permits resolution of the chiral WO93/10127 PCT/US92~09845 ~
2123128 12 ~
center ~ to the boron atom, using known per se methods for separation of diastereomers, such as HPLC, or fractional crystallization. This is illustrated in the reaction scheme of Figure l, where the isomers of the compound of formula VI in which the boronic acid is protected with (lS,2S,3R,5S)~ pinanediol can be separated by HPLC to give compounds VIa and VIb.
Alternatively, the isomers of the hydrochloride of the compound of formula VII, with the same boron protecting group, may be separated by fractional crystallization in a solvent such as ethyl acetate, or a dichloromethanetethyl acetate mixture, isopropanol, or ethanol to give compound VIIb as a single isomer with the ~ configuration at the carbon attached to boron. ~-.
A further advantage of using pinanediol is that the boronate esters so formed are more stable than those derived from other diols, for example, pinacol, with which significant loss of the protecting group is often observed during chromatography. This is useful in both purification and isomer separation by -chromatography on silica gel, since better recovery of the desired material is achieved.
In a slight modification of the synthesis described above, a derivatized pyrrole of formula III can be directly esterified with a diol of the formula V. iThe resulting ester of the formula IIIA
WO93/101~7 PCT/US92/0~
~ \ ~x (IIIA) can be reduced in the same manner as the compound of formula III, yielding the protected prolineboronic acid ester of formula VI. In other words, the order of the steps in which the pyrrole ring is reduced and the boronic acid group is esterified may be reversed.
The prolineboronic acid esters thus produced are easily coupled to activated carboxylic acids such as .
those typically used in peptide synthesis, for example a nitrogen-protected amino acid to yield a compound of the formula X
~ O
H N ~ X ( X ) R 2~0~f~N~ O
wherein -COOR2 is an amino protecting group of the sort commonly used in peptide synthesis, so that R2 is, for example, tert-butyl, benzyl, or fluorenylmethyl, and R3 is the side chain of a naturally occurring amino acid, optionally with appropriate protecting groups of the sort commonly used in peptide synthesis.
W0~3/10127 PCT/US92/09~
21231~ 14 Compounds of formula X contain protecting groups both on the boronate and on the amino acid nitrogen. It may be necessary to remove either or both protecting groups for biological activity or for further chemical manipulation. The protecting groups may be removed in either order. Various methods for removing these protecting groups are described below.
Removal of the nitrogen protecting group may be achieved by known methods to yield a compound of the formula XI. -~\y~-~/o\
H2N ~ ~ X (XI) 'I :
R
.
The ester group which protects the boronic acid moiety is stable to neutral and acidic organic media but many boronate esters are cleaved rapidly under mildly basic (pH - 7.5) aqueous conditions to yield the boronic acid. In the case of boronate esters of pinanediol, however, hydrolysis is known to be difficult, and special conditions are required for removal of the pinanediol. See for example Matteson et al. rJ. Am.
Chem. Soc., 102, 7590 (1980)] and Brown et al. [J.
Organometallic Chem., 385, lS (1988)]. These methods are not suitable for the removal of pinanediol from a compound of formula VI, X, or XI. We have found several methods for removal of pinanediol from a boronate such as compound VI, X or XI. Thus, removal W093/10127 PCT/US92/09~5 of the pinanediol may be achieved under mild conditions using an oxidizing agent capable of cleaving l,2 diols to remove the pinanediol from the equilibrium and hence drive it in the direction of the free boronic acid. For example, treatment of compounds of formula VI and X, in which the protecting group is pinanediol, with sodium metaperiodate in a~ueous ammonium acetate and acetone at ambient ' temperature yields compounds of formula IV and XII, respectively.
\
V ~ N ~ O OH (XII) O R3 ' This reaction is conveniently carried out in water, optionally with an added buffer such as ammonium acetate or disodium hydrogen phosphate, at a pH
between 3 and lO, preferably 6 to 8, and a temperature of O to 80 C, preferably 20 to 40 C, in the presence of a water miscible organic cosolvent such as acetone, methanol, ethanol, THF, or acetonitrile. Suitably the oxidizing agent is a non-nucleophilic oxidant capable of cleaving l,2-diols,such as periodic acid or its salts or permanganate salts. Under these conditions oxidative cleavage of the carbon-boron bond is not observed. It will be appreciated that this method is applicable to any boronic acid protected with pinanediol. Furthermore, it is applicable to any boronate protecting group which is a l,2-diol, , WO93/10127 PCT/US92/~
although it is particularly useful for protecting groups where simple aqueous hydrolysis is slow or incomplete.
In the case of a pinanediol boronate ester of a compound containing an unprotected amine, such as a compound of formula XI, the method described above may also be employed, but a second new method is prererable for compounds of this type. This me'hod consists of applying an aqueous solution of a compound of formula XI, at pH 4 or lower, to a column of a cation exchange resin, and eluting the column with water or dilute acetic acid to remove the pinanediol.
This remo~es the pinanediol from the equilibrium, and thus drives the reaction in the direction of hydrolysis. The column is then eluted with dilute aqueous ammonium hydroxide to remove the product, which after evaporation and acidification is obtained as a salt of the compound of formula XIII.
.~
. .
\ (XIII) H2N ~ OH
Suitably, a strongly acidic cation exchange resin, for example a sulfonic acid type of resin is used, such as, for example, Dowex 50. The pinanediol eluted from the resin may be recovered from the water solution and reused. This is most conveniently achieved by passing the water solution through a W093/10127 PCT/US92/09~5 ,.
column of a nonionic polymeric adsorbent, such as Amberlite XAD-200, which adsorbs pinanediol :
almost quantitatively. The pinanediol is removed from the column by elution with methanol or ethanol. The two operations of ion exchange and pinanediol adsorption may be combined in a single process in ;
which water is recycled from one column to the other using a pump. This has the advantage of requiring much smaller amounts of water, and allows the process to be continued long enough to achieve a high conversion to the product.
Persons skilled in the art will appreciate that the above-described method for removing pinanediol using a cation exchange resin is only appropriate for compounds containing a basic functional group, such as an unprotected amine.
A third method ls also applicable to pinanediol esters of compounds containing an unprotected amine, such as a compound of the formula XI. This method consists of transesterification of the pinanediol boronate with another boronic acid of the formula R4-B(OH)2, in a two-phase system. R4 represents a Cl 12 hydrocarbon group, which may be composed of straight, branched or cyclic alkyl chains and phenyl rings.
R4 is preferably phenyl. One of the phases is water adjusted to a pH below 7, preferably pH 1-4, and the other is a hydrocarbon organic solvent such as hexane, petroleum ether, or toluene. Thus, treatment of a compound of formula XI with phenylboronic acid in a mixture of water at pH l and hexane, followed by separation of the phases, produces the pinanediol ester of phenylboronic acid in the organic phase, WO~3/10~27 PCT/US92/09845 ,f"~ '~
21~12~ 18 which may be recovered simply by evaporation, and a solution of the free boronic acid of formula XIII in the aqueous phase, which may be isolated using an ion exchange resin in a similar manner to that described above. In this system the only component which is soluble in the organic ph~se is the pinanediol phenylboronate, thus removing the pinanediol from the equilibrium. The compound of formula XI, and the compound of formula XIII which is formed, both remain' in the aqueous layer, since neither are soluble in `
hydrocarbon solvents. The reaction may be carried out with any boronic acid with a hydrocarbon sidechain, providing its pinanediol ester is soluble in hydrocarbon solvents.
The fully deprotected compound of formula XIII may also ~e prepared by removal of the nitrogen protecting group from a compound of the formula XII using known methods. It will be appreciated that compounds of formula X, XI, XII, and XIII generally posess two chiral centers. One is adjacent to the boron atom, and the other is present in the amino acid moiety, except when that moiety is glycine. It will be further appreciated that the pure single diastereoisomers of these compounds are more desirable for biological use than mixtures of diastereoisomers.
Accordingly it is important to be able to produce these compounds as pure single isomers. In principal, since amino acids are generally available as single enatiomers, this may be achieved by separating the mixture of diastereoisomers formed by coupling an optically pure amino acid with racemic prolineboronic acid, using known techniques. Nevertheless, it has Wo93/1~127 PCT/USg~/09B45 2~ 23 1 2~ -been found that, except in the special case of valine, such separations are often difficult and time consuming. Thus it is preferable to use a form of prolineboronic acid which is a single isomer at the chiral center adjacent to boron, since no isomer separation is then necessary after coupling to an optically pure amino acid. The present invention provides an easy means for resolving the enantiomers of prolineboronic acid.
The following examples further illustrate the invention.
.
Example 1 ~ Dimethylethoxycarbonyl)-pyrrole-2-boronic acid To a solution of tetramethylpiperidine (8.8 mL, 52 mmol) in THF (275 mL~ at -7~ C under an argon atmosphere was added a 2M solution of butyllithium in hexanes (26 mL, 52 mmol~. After 15 min, l-tl,1-dimethylethoxycarbonyl)-pyrxole (8.35 g, SOmmol) in TH~ (10 mL) was added and the solution was stirred for 4 h at -78 C. Triethylborate ~30 mL, 17Ç mmol) was then added ~nd the mixture was allowed to warm to room temperature over 3 h. After an additional 12 h the reaction mixture was diluted with ether (500 mL) and washed with lM aqueous KHS04 (3 x 100 mL) followed by lM aqueous NaHC03 ~1 x 100 mL)..
Drying over MgS04 and rotary evaporation produced a brown solid which was purified by flash chromatography over silica gel (1:9 EtOAc:Hexane) to yield 8.7 g (82~) of a white crystalline solid (mp 101.0 -101,5 C).
... , .. . ~ , WO93/~01~7 PCT/U~92/09~5 ~ 1 2 8 20 lH NMR ~CDC13) ~ 1.65 (s, 9 H), 6.26 (t, J = 3.3 Hz, 1 H), 7.10 (dd, J = 1.6, 3.2 Hz, lH), 7.15 (s, 2 H), 7.44 (dd, J = 1.6, 3.2 Hz, lH); 13C NMR
(CDC13) 27.9, 85.5, 112.0, 127.Q, 128.7, 152.0; ~-CIMS m/z (% rel int) 212 (MH+, 11), 156 (100), 138 (68); Anal. Calcd for CgH14BN04: C, 51.23, H~
6.69, N, 6.64. Found: C, 51.22, H, 6.51, N, 6.67.
Example 2 ~ DimethylethoxYcarbonyl)-~yrrolidine-2-boronic acid A solut'on of 6.15 g (24 mmol) of dimethylethoxycarbonyl)-pyrrole-2-boronic acid, produced as in Example 1, in EtOAc (100 m~) was hydrogenated over 5~ Pt / C (ca. 500 mg) at 50 psi for 24 to 48h. The resulting suspension was filtered through a pad of Celite and concentrated. This material was chromatographed on silica gel using sequential elutions of 9:1 hexanes:EtOAc then acetone. The acetone fractions were concentrated to ~-produce 6.05 g (97%) of the desired compound as a clear glass that crystallized upon removal of trace solvents (mp 100-101C~.
H NMR (CDC13): ~ 1.42 (s, 9 H), 1.6 - 2.15 (m, S H), 3.1 - 3.6 (m, 2 H); C NMR (CDC13) ~ !
25.1, 25.7, 28.4, 45.6, 46.2, 78.6, 154.5; CIMS m/z (%
rel int) 116 (100), 70 (46); Anal. Calcd for CgH18BNO4: C, 50.27, H, 8.44, N, 6.51.
Found: C, 50.52, H, 8.22, N, 6.58.
WO93/10127 PCT/U~92/09845 , .
ExamPle 3 (lS,2S,3Rt5S3-Pinanediol l-(l 1-dimethylethoxY-carbonYl)-pYrrolidine-2S-boronate and LlS.2s ! 3R,5S)-Pinanediol 1-(1 1-dimethvl-ethoxycarbonyll~ yrrolidine-2R-boronate I
A solution of l-(l,1-dimethylethoxycarbonyl)-pyrrolidine-2-boronic acid, produced as in Example 2, (1.52 g, 7.1 mmol) and (lS,2S,3R,5S)-(+)-pinanediol ~1.36 g, 8.0 mmol) was stirred at room temperature in ether (2S mL3 for 2 h. Concentration and flash ch~omatography over silica gel (85:15 hexanes:EtOAc) produced 2.1 g (85%) of a 1:1 mixture of the two diastereomers. These were separated by HPLC over a 300 X 3.9 mm column of microporasil A eluting with methyl tert-butyl ether:hexanes (1:9) and using u.v.
detection at 220 nm. The isomer (lS,2S,3R,5S)-pinanediol l-(1,1-dimethyl-ethoxycarbonyl)-pyrrolidine-2S-boronate eluted first under these con~itions.
S-isomer: lH NMR (C6D63: ~ 0.55 (s, 3 H), 1.09 (s, 3 H), 1.52 (s, 9 H), 1.60 (s, 3 H), 1.2 - 2.2 (m, 8 H), 3.1 - 3.5 (m, 3 H), 4.11 tm, 0.3 H), 4.33 tm, 0.7 H); C NMR (C6D6): 6 23.9, 26.6, 27.1, 27.3, 28.4, 28.6, 28.8, 36.0, 38.2, 39.9, 46.1, Sl.9, ~-78.3, 78.5, 85.7, 154.9.
WO93/10127 PCT/~S92/~9~S
~123~28 22 R-isomer: lH NMR (C6D6): ~ 0.52 (s, 3 H), 1.08 -~
(s, 3 H), 1.52 (s, 9 H), 1.61 ~s, 3 H), 1.2 - 2.2 (m, 8 H), 3.1 - 3.6 (m, 3 H), 4.01 (m, 0.3 H), 4.25 (m, 0.7 H~; 13C NMR (C6D6) 23.9, 26.6, 27.1, 27.3, 28.4, 28.7, 28.9, 35.8, 38.2, 39.6, 46.2, 51.B, 78.1, 78.5, 85.7, 154.5.
It will be recognized that ~lR,2R,3S,5R)-pinanediol-l-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2S-borona~e and (lR,2R,3S,5R)-pinanediol-~-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2R-boronate could be produced in an analogous manner, starting with (lR,2R,3S,5R)-(-)-pinanediol.
Example_4 -~
rlS.2S.3R~5S)-Pinanediol ~yrrolidine-2S-boronate ~-hvdrochloride A solution of (lS,~S,3R,5S)-pinanediol- -1-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2S-boronate, produced as in Example 3 (28.5 mg, 0.08 mmol) was stirred in a solution of dry HCl in EtOAc (approximately 3M). After 2 h the solution was concentrated twice from EtOAc to produce 21.2 mg (91~) of the desired hydrochloride as a white solid (mp 204C (dec)).
1H NMR (CDCl3): ~ 0.83 (s, 3 H), 1.14 (d, J =
llHz, 1 H), 1.29 (s, 3 H), 1.45 (s, 3 H), 1.85 - 2.15 ~m, 6 H), 2.17 - 2.50 (m, 3 H), 3.18-3.25 (m, 1 H), 3.45 (bs, 2 H~, 4.42 (dd, J = 1.8, 8.6Hz, 1 H), 8.80 WO93/10127 P~T/US~2/09~S
. . ~., 2123l28 (bs, lH~, 10.56 (bs, lH); C NMR (CDC13): ~
23.9, 24.5, 26.5, 27.0, 27.2, 28.4, 34.9, 38.2, 39.4, 45.8, 51.2, 79.0, 87.6; CIMS m/z (~ rel int) 250 (MH+, 100); HRMS (EI) for C14H24BNO calcd 249.1900, found ~49.1899.
It will be recognized that (lR,2R,3S,5R)-pinanediol- ~
pyrrolidine-2S-boronate hydrochloride could be made in ~;-an analogous manner.
Example 5 (lS 2S 3R,5S)-Pinanediol pyrrolidine-2R-boronate hy~rochloride A solution of ~lS,2S,3R,5S)-pinanediol-l-(l,l-dimethylethoxycarbonyl)-pyrrolidine-2R-boronate, produced as in Example 3 (18.3 mg, 0.05 mmol) was treated with dry HCl in EtOAc as above. Work~up produced 14.3 mg (96~) of the desired hydrochloride as a white solid (mp 248 oC (dec)).
1H NMR (CDC13): ~ 0.83 (s, 3 H), 1.14 (d, J =
llHz, 1 H), 1.29 (s, 3 H~, 1.45 (s, 3 H), 1.85 - 2.15 (m, 6 H), 2.17 - 2.50 (m, 3 H), 3.18-3.25 (m, 1 H), 3.45 (bs, 2 H), 4.42 (dd, J = 1.8, 8.6Hz, 1 H), 8.80 (bs, 1 H), 10.56 (bs, 1 H); 13C NMR (CDCl ~ ~
23.9, 24.5, 26.5, 27.0, 27.2, 28.S, 34.9, 38.1, 39.4, 45.8, 51.2, 79.0, 87.8; CIMS m/z (% rel int) 250 (MH~, 100); HRMS (EI) for C14H24BN02 calcd 249.1900, found 249.1903.
WO 93~10127 PCI`/USg2/Og845 -212312~
It will be recognized that (lR,2R,3S,5R)-pinanediol pyrrolidine-2R-boronate hydrochloride could be made in an analogous manner.
Example 6 (lS~2S~3R,5s)-Pinanediol dimethylethoxvcarbonvl)-pyrrole-2-boronate A solution of 1-(1,1-dimethylethoxycarbonyl)-pyrrole-2-boronic acid, produced as in Example (1.36 g, 6.45 mmol) and (lS,2S,3R,5S)-(+)-pinanediol (1.10 g, 6.45 mmol) was stirred in 20 mL of ether for 4 h. Rotary evaporation followed by flash chromatography over silica gel (95:5 hexane:EtOAc) `~
produced 1.83 g (82%) of the desired product as a clear oil.
H NM~ (CDC13): ~ 0.90 (s, 3 H), 1-30 (s, 3 H~, 1.41 (dj J = 11 Hz, 1 H), 1.50 (s, 3 H), 1.50 (s, 3 H), 1.59 (s, 9 H), 1.96 (m, 2 H), 2.21 (t, J = 6Hz, 1 H3, 2.16 - 2.40 (m, 2 H), 4.45 (dd, J = 2, 8Hz, 1 H), ~;
6.20 (t, J = 3Hz, 1 H), 6.65 (d, J = 3Hz, 1 H), 7.40 (d, J = 3Hz, 1 H); 13C NMR (CDC13): ~ 24.0, 26.4, 27.2, 28.1, 28.6, 35.5, 38.3, 39.8, 51.8, 79.8, 83.6, 83.9, 111.6, 123.2, 124.7, 150.0; CIMS m/z (%
rel int) 346 (MH+, 4), 246 (81), 153 (100), 135 (56).
It will be recognized that (lR,2R,3S,5R)-pinanediol-1-(1,1-dilnethylethoxycarbonyl)-pyrrole-2-boronate could be made in an analogous manner.
WO93/10127 PCT/US92~0~5 . ~ .
2123:~28 Example 7 -~ DimethYlethoxvcarbonyl~-PYrrolidine-2-boronic acid from 1~ dimethylethoxvcarbonyl)-pYrrolidine To a solution of 1-(1,1-dimethylethoxycarbonyl)-pyrrolidine (17.1 g, 100 mmol) in diethyl ether (200 mL) at -78 C under an atmosphere of nitrogen was added 1.3M sec-butyllithium in cyclohexane (92.3 mL, 120 mmol) whilst maintaining the temperature below -60 C. After addition was complete, the reaction mixture was stirred at -7~ C for 4 h.
Trimethylborate (31.1 g, 300 mmol) was added and the mixture was allowed to warm to room temperature over 3h; After an additional 12h, water (150 mL) was added followed by 2M NaOH (200 mL~. The aqueous phase was isolated and the organic phase was reextracted with 2M
NaOH (150 mL). The combined basic extracts were acidified to pH 3 using 2M HCl and extracted using EtOAc (5 x 200 mL). The combined organic extracts were dried (Na2SO4) and concentrated to afford the desired product as a white crystalline solid (15.49g, 72%), identical with the material produced in Example Example 8 flS,2S,3R,5S)-Pinanediol 1-(1 1-dimethYlethoxycarbonvl)-pyrrolidine-2RS-boronate To a stirred solution of the material obtained in Example 7 (15.49 g, 72.0 mmol) in chloroform (250 mL) was added (lS,2S,3R,5S)-(+)-pinanediol (12.77 g, WO93/10127 PCT/US~2/09~5 21~31~ 26 75 mmol~. After stirring at room temperature under a nitrogen atmosphere for 16 h, the solvent was removed and the residue purified via flash chromatography over silica gel (hexane/EtOAc 9:1, 4:1) to give the desired product as a 1:1 mixture of diastereomers as an oil (23.62 g, 67.7% based on l-(l,1-dimethyl-ethoxycarbonyl)-pyrrolidine). This was identical with ~-the mixture of isomers produced in Example 3.
H NMR (CDCl3): ~ 0.85 (s, 3H), 1.12-1.21 (m, lH), 1.29 (s, 3H), 1.41 (s, 3H), 1.45 (s, 9H), 1.81-2.20 (m, 8H~, 2.28-2.39 ~m, lH), 3.04-3.18 (m, lH), 3.34-3.45 ~m, 2H), 4.28-4.38 (m, lH); 13C NMR
(CDCl3): ~ 23.7, 26.2, 27.1, 28.5, 35.5, 38.2, 39;6, 46.1, 78.0, 78.8, 85.7, 85.8, 154.7; CIMS m/z (~
rel int) 350 (MH+j 100), 294 (72), 250 (30).
ExamPle g Analvtical Method for the Diastereoisomers of (lS 2S,3R,5S)-Pinanediol PYrrolidine-2-boronate hydrochloride.
A reagent solution of Q.2 M phenyl isothiocyanate in dichloromethane-triethylamine (9:1~ was prepared. The sample to be analyzed (1-5 mg) was treated with 10 ~L of the reagent solution per ~mole of analyte and the clear solution was allowed to stand at room temperature for 15 min. A 1 ~L sample of the solution was then diluted in 1.00 mL of HPLC-grade acetonitrile and 10 ~L of this solution was analyzed by ~PLC (column: YMC AQ-303 S-5 120A, 4.6 x 250 mm;
WO93/10127 PCT/US92/09~5 - ~12~ l ~8 mobile phase: 65% MeCN - 35~ 25 mM ammonium phosphate, pH 7.5; flow rate l mL/min; detection by W at 254 nm). The phenylthiourea derivative of the R isomer of proline boronic acid elutes at about 6.4 min, its epimer elutes at about 7.8 min, and unreacted phenyl isothiocyanate, which serves as an internal standard, elutes at 12.2 min. .
Example 10 (ls~2s~3R~ssL~pinanediol p~rrolidine-2RS-boronate hvdrochloride A stirred solution of ~lS,2S,3R,5S)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2RS-boronate ~224 g, 0.64 mol) in diethyl ether (900 mL) was cooled in ice and dry HCl gas passed into the solution for 35 min at 10-18 C. The solution was stirred at room temperature overnight, cooled again in ice and the precipitate filtered off. The solid was washed with cold ether (400 mL) followed by petroleum ether/diethyl ether 9:1 (200 mL~ and dried under ~acuum to give the desired hydrochloride as a white solid (113 g, 62~) (mp 228-234C). Analysis of this material by HPLC as described in Example 9 showed it to be a 60:40 mixture of R:S isomers of the boronic acid.
WOg3~1~127 PCT/US92/09~5 212~1~8 1H NMR ~CDC13): ~ 0.83 (s, 3 H), 1.14 (d, J =
llHz, 1 H), 1.29 (s, 3 H), 1.45 (s, 3 H), 1.85 - 2.15 (m, 6 H), 2.17 - 2.50 (m, 3 H), 3.18-3.25 (m, 1 H), 3.45 (bs, 2 H), 4.42 (dd, J = 1.8, 8.6Hz, 1 H), 8~0 (bs, 1 H), 10.56 (bs, 1 H); C NMR lCDCi3) 23.9, 24.5, 26.5, 27.0, 27.2, 28.4, 34.9, 38.2, 39.4, 45.8, 51.2, 79.0, 87.6r CIMS m/z (% rel int) 250 (MH~, 100); Anal. Calcd for C14H24BNO2. HCl: C, 58.87, H, 8.B2, N, 4.90, Cl, 12.41. Found: C, 58.40,~
H, 8.86, N, 4.81, Cl, 12.39.
A similar reaction on a 29 g, 101 mmol scale using ethereal HCl (approx. 4.5M, 200 mL~ and EtOAc (150 mL) as solvent yielded the hydrochloride (11.1 g, 47%) as a B1:19-mixture of R:S isomers Example 11 -. :
(lS,2S,3R~ inanediol Pvrrolidine-2R-boronate hYdrochloride bY fractional crvstallization.
~ ' Method ~: ;
The 60:40 isomeric mixture obtained in Example 10 `
(1.18 g 4.13 mmol) was dissolved in CH2C12 (65 mL) with slight warming, and the solution filtered. The filtrate was diluted with EtOAc (65 mL) and crystallization began within a minute. The suspension was stirred for 1-2 h at room temperature and the first crop of solid was collected and the ;~- diastereomeric ratio determined as described in Example 9 (540 mg, 46%, R:S ratio 97.1:2.9). Solvent WO~3~0127 PCT/US92/09 was distilled from the filtrate until most of the CH2C12 was removed, then the residual EtOAc solution was stirred at room temperature overnight to afford a second crop of off-white solid (346 mg, 29~, R:S ratio 39.2:60.8). The first crop was recrystallized from isopropyl alcohol (10 mL) to afford 430 mg (80%
recovery) of material >99% 2-R isomer. (mp 269-272 C
(dec)) ~]25D +0~70O (c=1.15, MeOH) H NMR ~CDC13): ~ 0.83 (s, 3 H), 1.14 (d, J =
llHz, 1 H), 1.29 (s, 3 H), 1.45 (s, 3 H), 1.85 - 2.15 (m, 6 H), 2.17 - 2.50 (m, 3 H), 3.18-3.25 (m, 1 H), 3.45 ~bs, 2 H), 4.42 (dd, J = 1.8, 8.5Hz, 1 H), 8.80 (bs, 1 H), 10.56 (bs, 1 H); l C NMR (CDC13) ~
23;9, 24.5, 26.5, 27.0, ~7.2, 28.5, 34.9, 38.1, 39.4, 45.8, 51.2, 79.0, 87.8; CIMS m/z (% rel int) 250 (MH+, 100); Anal. Calcd for C14H~4BN~2. HCl: C, 58.87, H, 8.82, N, 4.90, Cl, 12.41. Found: C, 58.64, H, ~.79, N, 4.90, Cl, 12.66.
Method B:
r A suspension of (lS,2S,3R,5S)-pinanediol-pyrrolidine-2RS-boronate hydrochloride as a 1:1 mixture of isomers (850 mg, 2.98 mmol) in EtOAc (60 mL) was heated under reflux with stirring for 4 h. The mixture was filtered hot and the collected solid dried to give material enriched in the R isomer (541 mg 64%~, R:S ratio 2:1. Evaporation of the filtrate yielded material enriched in the S isomer ~217 mg), R:S = 1:4. The filtered solid (500 mg) was treated in the same way with EtOAc (45 mL) for 1.5 h and again filtered hot to yield a solid (366 mg, 73%), R:S = 7:1. This material was again treated with EtOAc ~V093/10127 PCT/US92~0~5 ', ,, ~123~2~ :~
(38 mL) for 1.5 h. The solid isolated (287 mg, 78%) now had R:S ratio 97:3. The spectral properties were the same as those of material obtained by method A.
'':
Example 12 - ~-1-(l,i-DimethylethoxycarbonYl)-pyrrolidine-2-boronic acid from (lS,2S,3R,5S) pinanediol 1-(1,l-dimethylethox~carbonYl)-Pyrrolidine-2-boronate To a solution of (lS,2S,3R,5S)-pinanediol-~ dimethylethoxycarbonyl)-pyrrolidine-2RS-boronate ~-from Example 8 (1.9 g, S.44 mmol) in acetone (80 mL) wa~ added O.lM ammonium acetate solution (80 mL) and sodium metaperiodate (3.49 g,16.33 mmol). The reaction mixture was stirred at room temperature for 40 h, then the acetone was evaporated and the residue was treated with 2M NaOH solution. This a~ueous phase ;
was washed with CH2C12 (2 x 80 mL), acidified with 2M HCl to pH 3 and extracted with CH2C12 (4 x 80 mL). The combined organic extracts were dried (Na2S04) and concentrated to afford the desired product as a white foamy solid (890 mg, 76%), identical by NMR with the material prepared in Example ~;
2. The boronic acid was derivatized with pinacol for purposes of analysis.
' W O 93/10127 P(~r/US92/09845 ~1231 2~
Example 13 Pinacol ~ dimethYlethoxycarbonyl)- :
Pyrrolidine-2Rs-boronate To a stirred solution of the boronic acid from Example 12 (890 mg, 4.14 mmol) in chloroform was added pinacol (489 mg, 4.14 mmol). After stirring for 16h at room temperature, the solvent was removed and the residue was purified via chromatography over silica gel (hexane/EtOAc, 4:1) to give the desired product as a white solid (1.04 g, 85%) (mp 73-75 C).
H NMR (CDCl3): ~ 1.18 (s, 6H), 1.21 (s, 6H), 1.38 ~s, 9H), 1.5.-2.00 (m, 4H), 2.9$ (br s, lH), 3.27 (m, 2H~; 13C NMR (CDCl3): ~ 24.3, 24.5, 24.7, 24.~, 25.3, 27.0~ 27.6, 28.4, 2~.6, 43.6, 45.8, 46.3, 78~8, 83.2, 154.4, 154.8; CIMS m/z (% rel int) 29~
(18), 242 (100, MH+ - tBu), 198 (30, MH+ - Boc); Anal.
Calcd for C15H28BNO4: C, 60.62, H,9.50, N, 4.71.
Found: C, 60.94, H, 9.65, N, 4.88.
ExamPle 14 N~ DimetbvlethoxYcarbonYl)-L-valvlpyrrolidine-2R-boronate (lS 2S 3R 5S)-Pinanediol ester A solution of t-BOC-L-Valine (351.7 g, 1.62 mol) in CH2Cl2 (1.6 L) was cooled with an ice bath and a solution of dicyclohexylcarbodiimide (161.8 g, 0.784 mol) in CH2C12 (0.75 L) was added within 40 min at 0-2 C. After addition the solution was WO~3/10127 PCT/US92/09~5 `
; ; ~
stirred for 3.5 h at 0-5 C. The white precipitate was filtered off and washed with CH2Cl2 (0.2 L). The resulting clear solution was added at 18-20 C
(waterbath cooling) to a solution of -~
(lS,2S,3R,5S)-pinanediol pyrrolidine-2RS-boronate hydrochloride (210 g, 0.73S mol), prepared as in Example lO, in CH2Cl2 (2.0 L) containing N-methylmorpholine (164 g, 1.62 mol). The mixture was allowed to stir at~room temperature overnight. The cloudy solution was filtered through a 16 cm dia. x 2 cm high bed of silica gel (200-425 mesh) and washed wlth CH2Cl2 (1.5 ~). The solvent was evaporated to yield a highly viscous oil (542 g). This oil was dissolved in ethyl acetate (0.7 L~ and the mixture cooled in an ice bath. Crystals formed, which were filtered off at low temperature, and washed with cold ethyl acetate (0.1 L). The wet filter cake was transferred into petroleum ether (0.65 L) and stirred at room temperature for 1 h. The white solid was filtered, washed with cold petroleum ether (0.1 L), and dried to constant weight to yield the title compound as a white solid ~113.4 g) (mp 128-13~ C).
ll the mother Iiquors were combined and concentrated to a volume of approx. 0.8 L. After standing for 2 days in the freezer a solid formed, which was filtered off, and treated with petroleum ether as above to yield a beige solid (50.4 g). This was a mixture of impurities and the unwanted diastereoisomer. The mother liquor from above was concentrated and the residue purified over a silica gel column (14 cm dia.
x 60cm) using héxane/ethyl acetate (85:15) (14 L). ~;
Appropriate fractions were collected, treated with -petroleum ether, the solid collected by filtration and f ';
WO93/10~27 P~T/US92/~9845 .....
~,~
212312~
dried, to yield more desired product ~18.5 g). The other diastereoisomer was also obtained (7.5 g) (mp 82-83 C). A second column was performed on the combined mixed fractions and mother li~uors to yield additional pure compound (13.5 g), total combined yield 145.4 g t44.3%) of desired diastereoisomer (mp 128-130 C).
H NMR (CDCl3): ~ 0.83 (s, 3 H), 0.91 (d, J =
6.7Hz, 3 H), 0.97 (d, J = 6.7Hz, 3 H), 1.27 (s, 3 H), 1.35-1~45 (m, 1 H), 1.39 (s, 3 H), 1.41 (s, 9 H), 1.72-2.14 (m, 9 H), 2.26-2.36 (m, 1 H), 3.15 (dd, J =
6.7, lO.lHz, 1 H), 3.43-3.51 (m, 1 H), 3.70-3.81 (m, l H), 4.19-4.28 tm, 2 H), 5.29 (d, J - 9.2~z, 1 H);
3~C NMR (CDCl3): ~ 17.3, 19.2, 24.0, 26.3, 27.1 27.2, 27.4, 28.4, 28.6, 31.4, 33.9, 35.5, 38.2, 39.6, 46.7, 51.2, 56.6, 77.8, 79.2, 85.8, 155.9, 170.2; CIMS
m/z (~ rel int) 449 ~MH~, 100), 393 (50); Anal. Calcd for C24H41BN2O~: C, 64.28, H, 9.22, N, 6.25.
Found: C, 64.58, H, 9.33, N, 6.52.
- ....
Example 15 L-valylpyrrolidine-2R-boronate (lS,2S,3R 5S)-pinanediol ester hydroqen maleate N-(1,1-Dimethylethoxycarbonyl)-L-valylpyrrolidine-2~-boronate (lS,2S,3R,5S)-pinanediol ester (248 mg, 0.553 mmol) was added to a stirred solution of dry hydrogen chloride in ethyl acetate. After 1.5 h the solvent was evaporated to leave the deprotected hydrochloride. The residue was partitioned between ' WO~3~10127 P~T/US92/0984~
212~128 34 CH2Cl2 and sodium carbonate solution, and the organic layer dried over magnesium sulfate. The organic layer contains the free base of the title compound, which exists as a cyclic form containing a nitrogen-boron bond, but reverts to the open form on adding acid. The organic solution was filtered into a solution of maleic acid (64 mg, 0.553 mmol) in methanol ~5 mL), and the solvent evaporated to leave a crystalline residue (258 mg), ~hich was recrystallized from ethyl acetate to give the title compound ~193 mg, 75%) (mp 145-146 C).
- H NMR ~CDCl3): ~ 0.84 (s, 3 H), 1-08 ~d, J =
6~9Hz, 3 H), 1.13 (d, J = 6.9Hz, 3 H), 1.26-1.31 (m, 2 H), 1.23 (s, 3 H), 1.38 ~s, 3 H), 1.72-2.15 (m, 7 H), 2.2~-2.38 (m, 2 H), 3.28 (dd, J = 6.9, 9.4 Hz, 1 H), 3.38-3.47 (m, 1 H), 3.73-3.78 (m, 1 H), 4.14 (d, J = 5.1Hz, 1 H), 4.26 (d, J = 7.1Hz, 1 H), 6.25 (s, 2 H), 7.5-9.0 (v. br, 4 H); C NMR (CDCl3): ~ ~
17.0, 18.4, 24.0, 26.3, 27.0, 27.1, 28.7, 30.0, 35.4, -38.2, 39.5, ~7.3, 51.2, 56.6, 78.1, 86.2, 135.5, 166.3, 169.5; CIMS m/z (% rel int) 349 (MH+, 100), 197 (18); Anal. Calcd for C23H37BN207: C, 59.49, : H, 8.03, N, 6.03. Found: C, 59.50, H, 8.13, N, 6.03.
.
.
WO9~/10127 ~CT/US92/09~5 Example 16 L-valYlpvrrolidine-2R-boronic acid methanesulfonate a) cyclo-L-valylpyrrolidine-2R-boronic acid ~
A solution of the maleate salt obtained in Example 15 -(5.0 g, 10.8 mmol) in dilute acetic acid (1.0%, 60 mL) was loaded on to a column (3.5 cm deep x 4 cm dia.) of Dowex 50X2-200 ion exchange resin in the H+ form. The .
column was then eluted with acetic acid (1.0%, 14 L~, water (42 L) and ammonium hydroxide solution (1:100 dilution of commercial 0.880 solution). Pinanediol could be recovered from the neutral and acidic : fractions. The product was found in early basic fractions, which were collected and washed with CH2Cl2 (2 x 100 mL). The organic extracts were dried and concentrated to afford recovered free base of thP starting material (741 mg, 20%), along with some pinanediol. The aqueous phase was lyophilized to afford the title compound, which exists in a cyclic .
form with a nitrogen-boron bond, as a white solid (1.52g, 66%) (mp 120-130C). -, : H NMR (D20) ~ 0 97 (d, J = 7.0 Hz, 3 H), 1.06 (d, J = 7.0 Hz, 3 H), 1.59-1.80 (m, 2 H), 1.95-2.03 : (m, 2 H), 2.41-2.51 (m, 1 H), 2.62-2.69 (m, 1 H), 3.23-3.32 (m, 1 H), 3.Sl-3.58 (m with overlapping doublet, J = 4.2 Hz, 2 H); 13C NMR (D20): ~
19.0, 21.7, 27.3, 30.7, 29.9, 49.6, 61.0, 170.3; IR
(cm 1) 3400-3314, 3221-3108, 2961-2872, 1637, 1452-1369; CIMS m/z (~ rel int) 375 (9o, WO93~0127 PCT/US92/09845 2 1 ~ 8 M2H+-3H20), 197 (100, MH+-H20)i Anal. Calcd for C9HlgBN203: C, 50.50, H~ 8.95~ N, 13-09-Found: C, 50.43, H, 8~76, N, 12.93.
b) L-valylpyrrolidine-2R-boronic acid methanesulfonate To a stirred suspension of the cyclized boronic acid obtained above (5.17 g, 24.16 mmol) in acetonitrile (190 mL) under nitrogen was added a solution of ' ~:
methanesulfonic acid (2.32 g, 24.16 mmol) in `.
acetonitrile (10 mL) dropwise over five minutes and the mixture stirred at room temperature for 2 h. The ~;
solid was collected by filtration, washed well with acetonitrile and diethyl ether and dried to afford the title compound as a white solid (6.14g, 82%) (mp 179-180 C). Crystallization of this ~aterial from dimethylformamide/acetonitrile ga~e a 70~ recovery of material in a single crop (mp 181-182 C).
- ;
H NMR (D20, phosphate, pH2): ~ 0.99 (d, J = 6.8 Hz, 3H), 1.09 (d, J = 6.9Hz, 3H), 1.69-1.75 (m' lH), 1.90-1.99 (m, lH), 2.10-2.14 (m, 2H), 2.28-2.35 ~m, lH), 2.80 (s, 3H), 3.07 (dd, J = 7.0 and 11.2 Hz, lH), 3.46-3.51 (m, lH), 3.75 ~t, J = 9.0 Hz, lH), 4.14 (d, J = 5.1 Hz, lH); the cis amide rotamer (ca. 3%) is also observed at 3.53-3.55 (m) and 3.83 (d, J =
6.2 Hz); 13C NMR: ~ 16.2, 18.4, 26.9, 27.1, 29.0, 38.8, 47.9, 49.0, 57.2, 167.2; peaks due to the cis amide rotamer are observed at 16.8, 24.3, 29.9, 57.8, -167.5; IR (cm ) 3387, 3000 (br~, 2972, 2655, 1646, 1370, 1197; CIMS m/z (% rel int, ethylene glycol adduct) 241 (MH+ 100); Anal. Calcd for C1oH23BN206S: C, 38.72, H, 7.47, N, 9.03.
Found: C,38.65, H, 7.45, N, 8.44.
Exam~le 17 N~ DimethvlethoxycarbonYl)-L-valylPvrrolidine-2R-boronic acid .
To a stirred solution of N-(l,l-dimethyl-ethoxycarbonyl)-L-valylpyrrolidine-2R-boronate ~lS,2S,3R,SS)-pinanediol ester, prepared as in Example 14, (1.0 g, 2.3 mmol) in acetone (75 mL) was added ammonium acetate solution (60 ml, 0.1 M) and sodium metaperiodate (1.48 g, 6.91 mmol). The reaction mixture was stirred at room temperature for 48 h, then the acetone was evaporated. The residue was treated with 2M sodium hydroxide solution (100 mL), and washed with CH2Cl2 (2 x 50 mL). The aqueou~ layer was carefully acidified with 2M hydrochloric acid to pH 3 and extracted with CH2Cl2 (4 x 70 mL). The combined organic extracts of the acid solution were dried over sodium sulphate and concentrated to afford the desired product as a white ~oamy solid (700mg, 97%). Further purification vi~ chromatography over silica gel (CH2Cl2/methanol, 9:1) gave the boronic acid again as a white solid (449 mg, 62%) (mp 82-92C).
H NMR (CDCl3~: ~ 0.95 (d, J = 5.7 Hz, 6H), 1.42 (s, 9H), 1.55-1.80 (m, lH) 1.80-2.20 (m, 4H), 2.89-3.07 (m, lH), 3.30-3.55 (m, lH), 3.55-3.65 (m, :
lH), 4.10-4.30 (m, lH), 5.34 (d, J = 9 2 Hz, lH);
1 C NMR (~DCl3): ~ 18.0, 19.1, 26.3, 27.7, 28.3, 31.2, 46.1, 52.0, 55.7, 79.5, lS5.6, 170.8; IR
(cm 1) 3395-3319, 2971-2875, 1711, 1619, 1400, 1174;
CIMS m/z (% rel int, ethylene glycol adduct) 341(MH , 100), 285(MH -tBu, 67), 241(MH -BOC, 21).
WO93/10127 PCT/~S92/09~5 .
Exam~le 18 L-valYlp~rrolidine-2R-boronic acid hydrochloride N-(1,1-Dimethylethoxycarbonyl)-L-valylpyrrolidine-2R ~-boronic acid, obtained in Example 17 (250 mg, 0.796 mmol) was stirred with HCl/ether (4.5M, 20 mL) at room temperature under nitrogen for 1.5 h. The solvent was then evaporated and the residue triturated with diethyl ether (3 x 10 mL) and each time the ether was decanted. The residue was dried to yield the title compound as a white powdery solid (172 mg, 86%) (mp 211-213C).
lH`NMR ~D2O, phosphate pH 2): ~ 0.99 (d, J = -~
6.9 Hz, 3 H), 1.09 (d, J = 7.0 Hz, 3 H), 1.67-1.76 (m, 1 H), 1.87-2.01 ~m, 1 H), 2.09-2.15 (m, 2 H), .~:
.28-2.35 (m, 1 H), 3.07 (dd, J = 7.0 and 11.4 Hz, 1 H), 3.48 (dt, 3 = 6.7 and 10.3 Hz, 1 H), 3.73 (dt, J = 1.7 and 10.2 Hz, 1 H), 4.14 (d, J = 5.2 Hz, 1 H);
3C NMR: ~ 16.0, 18.3, 26.9, 27.1, 28.9, 47.9, .
48.9, 57.2, 167.3; IR (cm ) 3400-2800, 3368, 2970l2880, 1635, 1475-1378, 1400; CIMS m/z (% rel int, e~hylene glycol adduct) 241 (MH , 100).
' WOg3~10127 PC~/US92/09 .
xample 19 2123128 cyclo-L-Valvlpyrrolidine-2R-boronic acid by transesterification with ~henylboronic acid A solution of L-valylpyrrolidine-2R-boronate -(lS,2S,3R,5S~-pinanediol ester hydrochloride, prepared -as in Example 15 ~500 mg, 1.3 mmol) in lM hydrochloric acid (10 mL) containing hexane (20 mL) and phenylboronic acid (500 mg, 2.6 mmol) was stirred vigorously for lh at room temperature. The hexane was removed by decantation, then more hexane (20 ml~ was added and the mixture stirred for a further 30 min.
The layers were separated and the combined hexane l~yers dried over sodium sulphate and concentrated to give pinanediol phenylboronate (331 mg, 99%) as a ..
white crystalline solid. The aqueous layer was then passed through a column of Dowex 50 ion exchange resin. The column was eluted with water (200 mL), followed by ammonium hydroxide solution (1:100 dilution of commercial 0.880 solution, 50 ml).
Isolation of the basic fractions followed by lyophilization gave the free boronic acid (230 mg, 83~) as a white powder, identical by NMR with the material obtained in Example 16a.
.
. .
groups. ~.
Accordingly, suitable diols of formula V are, for example, ethylene glycol, pinacol, catechol, pinanediol, butan-2,3-diol, 2,2-dimethyl propan 1,3-diol, diethanolamine and 1,2-diphenylethan-1,2-diol.
With the boronic acid moiety protected by the ester .
group, the protecting group on the nitrogen is next removed using known per se techniques, such as those described by Greene in "Protective Groups in Organic Synthesis" (J. Wiley & Sons, 1981), to yield the hydrochloride of the desired prolineboronic acid ester of the formula VII.
:: A
\ (VII) H 0'' ; ~:
, For example, when the protecting group is Boc, it may be easily removed with dry hydrogen chloride in ethyl acetate.
It is preferred to perform the esterification of the ;~
compound of formula IV with a chiral, non-racemic diol such as (lS,2S,3R,5S~ )-pinanediol, 1,2-diphenylethan-1,2-diol or butan-2,3,-diol, because :
so doing introduces additional chiral centers into the molecule. This permits resolution of the chiral WO93/10127 PCT/US92~09845 ~
2123128 12 ~
center ~ to the boron atom, using known per se methods for separation of diastereomers, such as HPLC, or fractional crystallization. This is illustrated in the reaction scheme of Figure l, where the isomers of the compound of formula VI in which the boronic acid is protected with (lS,2S,3R,5S)~ pinanediol can be separated by HPLC to give compounds VIa and VIb.
Alternatively, the isomers of the hydrochloride of the compound of formula VII, with the same boron protecting group, may be separated by fractional crystallization in a solvent such as ethyl acetate, or a dichloromethanetethyl acetate mixture, isopropanol, or ethanol to give compound VIIb as a single isomer with the ~ configuration at the carbon attached to boron. ~-.
A further advantage of using pinanediol is that the boronate esters so formed are more stable than those derived from other diols, for example, pinacol, with which significant loss of the protecting group is often observed during chromatography. This is useful in both purification and isomer separation by -chromatography on silica gel, since better recovery of the desired material is achieved.
In a slight modification of the synthesis described above, a derivatized pyrrole of formula III can be directly esterified with a diol of the formula V. iThe resulting ester of the formula IIIA
WO93/101~7 PCT/US92/0~
~ \ ~x (IIIA) can be reduced in the same manner as the compound of formula III, yielding the protected prolineboronic acid ester of formula VI. In other words, the order of the steps in which the pyrrole ring is reduced and the boronic acid group is esterified may be reversed.
The prolineboronic acid esters thus produced are easily coupled to activated carboxylic acids such as .
those typically used in peptide synthesis, for example a nitrogen-protected amino acid to yield a compound of the formula X
~ O
H N ~ X ( X ) R 2~0~f~N~ O
wherein -COOR2 is an amino protecting group of the sort commonly used in peptide synthesis, so that R2 is, for example, tert-butyl, benzyl, or fluorenylmethyl, and R3 is the side chain of a naturally occurring amino acid, optionally with appropriate protecting groups of the sort commonly used in peptide synthesis.
W0~3/10127 PCT/US92/09~
21231~ 14 Compounds of formula X contain protecting groups both on the boronate and on the amino acid nitrogen. It may be necessary to remove either or both protecting groups for biological activity or for further chemical manipulation. The protecting groups may be removed in either order. Various methods for removing these protecting groups are described below.
Removal of the nitrogen protecting group may be achieved by known methods to yield a compound of the formula XI. -~\y~-~/o\
H2N ~ ~ X (XI) 'I :
R
.
The ester group which protects the boronic acid moiety is stable to neutral and acidic organic media but many boronate esters are cleaved rapidly under mildly basic (pH - 7.5) aqueous conditions to yield the boronic acid. In the case of boronate esters of pinanediol, however, hydrolysis is known to be difficult, and special conditions are required for removal of the pinanediol. See for example Matteson et al. rJ. Am.
Chem. Soc., 102, 7590 (1980)] and Brown et al. [J.
Organometallic Chem., 385, lS (1988)]. These methods are not suitable for the removal of pinanediol from a compound of formula VI, X, or XI. We have found several methods for removal of pinanediol from a boronate such as compound VI, X or XI. Thus, removal W093/10127 PCT/US92/09~5 of the pinanediol may be achieved under mild conditions using an oxidizing agent capable of cleaving l,2 diols to remove the pinanediol from the equilibrium and hence drive it in the direction of the free boronic acid. For example, treatment of compounds of formula VI and X, in which the protecting group is pinanediol, with sodium metaperiodate in a~ueous ammonium acetate and acetone at ambient ' temperature yields compounds of formula IV and XII, respectively.
\
V ~ N ~ O OH (XII) O R3 ' This reaction is conveniently carried out in water, optionally with an added buffer such as ammonium acetate or disodium hydrogen phosphate, at a pH
between 3 and lO, preferably 6 to 8, and a temperature of O to 80 C, preferably 20 to 40 C, in the presence of a water miscible organic cosolvent such as acetone, methanol, ethanol, THF, or acetonitrile. Suitably the oxidizing agent is a non-nucleophilic oxidant capable of cleaving l,2-diols,such as periodic acid or its salts or permanganate salts. Under these conditions oxidative cleavage of the carbon-boron bond is not observed. It will be appreciated that this method is applicable to any boronic acid protected with pinanediol. Furthermore, it is applicable to any boronate protecting group which is a l,2-diol, , WO93/10127 PCT/US92/~
although it is particularly useful for protecting groups where simple aqueous hydrolysis is slow or incomplete.
In the case of a pinanediol boronate ester of a compound containing an unprotected amine, such as a compound of formula XI, the method described above may also be employed, but a second new method is prererable for compounds of this type. This me'hod consists of applying an aqueous solution of a compound of formula XI, at pH 4 or lower, to a column of a cation exchange resin, and eluting the column with water or dilute acetic acid to remove the pinanediol.
This remo~es the pinanediol from the equilibrium, and thus drives the reaction in the direction of hydrolysis. The column is then eluted with dilute aqueous ammonium hydroxide to remove the product, which after evaporation and acidification is obtained as a salt of the compound of formula XIII.
.~
. .
\ (XIII) H2N ~ OH
Suitably, a strongly acidic cation exchange resin, for example a sulfonic acid type of resin is used, such as, for example, Dowex 50. The pinanediol eluted from the resin may be recovered from the water solution and reused. This is most conveniently achieved by passing the water solution through a W093/10127 PCT/US92/09~5 ,.
column of a nonionic polymeric adsorbent, such as Amberlite XAD-200, which adsorbs pinanediol :
almost quantitatively. The pinanediol is removed from the column by elution with methanol or ethanol. The two operations of ion exchange and pinanediol adsorption may be combined in a single process in ;
which water is recycled from one column to the other using a pump. This has the advantage of requiring much smaller amounts of water, and allows the process to be continued long enough to achieve a high conversion to the product.
Persons skilled in the art will appreciate that the above-described method for removing pinanediol using a cation exchange resin is only appropriate for compounds containing a basic functional group, such as an unprotected amine.
A third method ls also applicable to pinanediol esters of compounds containing an unprotected amine, such as a compound of the formula XI. This method consists of transesterification of the pinanediol boronate with another boronic acid of the formula R4-B(OH)2, in a two-phase system. R4 represents a Cl 12 hydrocarbon group, which may be composed of straight, branched or cyclic alkyl chains and phenyl rings.
R4 is preferably phenyl. One of the phases is water adjusted to a pH below 7, preferably pH 1-4, and the other is a hydrocarbon organic solvent such as hexane, petroleum ether, or toluene. Thus, treatment of a compound of formula XI with phenylboronic acid in a mixture of water at pH l and hexane, followed by separation of the phases, produces the pinanediol ester of phenylboronic acid in the organic phase, WO~3/10~27 PCT/US92/09845 ,f"~ '~
21~12~ 18 which may be recovered simply by evaporation, and a solution of the free boronic acid of formula XIII in the aqueous phase, which may be isolated using an ion exchange resin in a similar manner to that described above. In this system the only component which is soluble in the organic ph~se is the pinanediol phenylboronate, thus removing the pinanediol from the equilibrium. The compound of formula XI, and the compound of formula XIII which is formed, both remain' in the aqueous layer, since neither are soluble in `
hydrocarbon solvents. The reaction may be carried out with any boronic acid with a hydrocarbon sidechain, providing its pinanediol ester is soluble in hydrocarbon solvents.
The fully deprotected compound of formula XIII may also ~e prepared by removal of the nitrogen protecting group from a compound of the formula XII using known methods. It will be appreciated that compounds of formula X, XI, XII, and XIII generally posess two chiral centers. One is adjacent to the boron atom, and the other is present in the amino acid moiety, except when that moiety is glycine. It will be further appreciated that the pure single diastereoisomers of these compounds are more desirable for biological use than mixtures of diastereoisomers.
Accordingly it is important to be able to produce these compounds as pure single isomers. In principal, since amino acids are generally available as single enatiomers, this may be achieved by separating the mixture of diastereoisomers formed by coupling an optically pure amino acid with racemic prolineboronic acid, using known techniques. Nevertheless, it has Wo93/1~127 PCT/USg~/09B45 2~ 23 1 2~ -been found that, except in the special case of valine, such separations are often difficult and time consuming. Thus it is preferable to use a form of prolineboronic acid which is a single isomer at the chiral center adjacent to boron, since no isomer separation is then necessary after coupling to an optically pure amino acid. The present invention provides an easy means for resolving the enantiomers of prolineboronic acid.
The following examples further illustrate the invention.
.
Example 1 ~ Dimethylethoxycarbonyl)-pyrrole-2-boronic acid To a solution of tetramethylpiperidine (8.8 mL, 52 mmol) in THF (275 mL~ at -7~ C under an argon atmosphere was added a 2M solution of butyllithium in hexanes (26 mL, 52 mmol~. After 15 min, l-tl,1-dimethylethoxycarbonyl)-pyrxole (8.35 g, SOmmol) in TH~ (10 mL) was added and the solution was stirred for 4 h at -78 C. Triethylborate ~30 mL, 17Ç mmol) was then added ~nd the mixture was allowed to warm to room temperature over 3 h. After an additional 12 h the reaction mixture was diluted with ether (500 mL) and washed with lM aqueous KHS04 (3 x 100 mL) followed by lM aqueous NaHC03 ~1 x 100 mL)..
Drying over MgS04 and rotary evaporation produced a brown solid which was purified by flash chromatography over silica gel (1:9 EtOAc:Hexane) to yield 8.7 g (82~) of a white crystalline solid (mp 101.0 -101,5 C).
... , .. . ~ , WO93/~01~7 PCT/U~92/09~5 ~ 1 2 8 20 lH NMR ~CDC13) ~ 1.65 (s, 9 H), 6.26 (t, J = 3.3 Hz, 1 H), 7.10 (dd, J = 1.6, 3.2 Hz, lH), 7.15 (s, 2 H), 7.44 (dd, J = 1.6, 3.2 Hz, lH); 13C NMR
(CDC13) 27.9, 85.5, 112.0, 127.Q, 128.7, 152.0; ~-CIMS m/z (% rel int) 212 (MH+, 11), 156 (100), 138 (68); Anal. Calcd for CgH14BN04: C, 51.23, H~
6.69, N, 6.64. Found: C, 51.22, H, 6.51, N, 6.67.
Example 2 ~ DimethylethoxYcarbonyl)-~yrrolidine-2-boronic acid A solut'on of 6.15 g (24 mmol) of dimethylethoxycarbonyl)-pyrrole-2-boronic acid, produced as in Example 1, in EtOAc (100 m~) was hydrogenated over 5~ Pt / C (ca. 500 mg) at 50 psi for 24 to 48h. The resulting suspension was filtered through a pad of Celite and concentrated. This material was chromatographed on silica gel using sequential elutions of 9:1 hexanes:EtOAc then acetone. The acetone fractions were concentrated to ~-produce 6.05 g (97%) of the desired compound as a clear glass that crystallized upon removal of trace solvents (mp 100-101C~.
H NMR (CDC13): ~ 1.42 (s, 9 H), 1.6 - 2.15 (m, S H), 3.1 - 3.6 (m, 2 H); C NMR (CDC13) ~ !
25.1, 25.7, 28.4, 45.6, 46.2, 78.6, 154.5; CIMS m/z (%
rel int) 116 (100), 70 (46); Anal. Calcd for CgH18BNO4: C, 50.27, H, 8.44, N, 6.51.
Found: C, 50.52, H, 8.22, N, 6.58.
WO93/10127 PCT/U~92/09845 , .
ExamPle 3 (lS,2S,3Rt5S3-Pinanediol l-(l 1-dimethylethoxY-carbonYl)-pYrrolidine-2S-boronate and LlS.2s ! 3R,5S)-Pinanediol 1-(1 1-dimethvl-ethoxycarbonyll~ yrrolidine-2R-boronate I
A solution of l-(l,1-dimethylethoxycarbonyl)-pyrrolidine-2-boronic acid, produced as in Example 2, (1.52 g, 7.1 mmol) and (lS,2S,3R,5S)-(+)-pinanediol ~1.36 g, 8.0 mmol) was stirred at room temperature in ether (2S mL3 for 2 h. Concentration and flash ch~omatography over silica gel (85:15 hexanes:EtOAc) produced 2.1 g (85%) of a 1:1 mixture of the two diastereomers. These were separated by HPLC over a 300 X 3.9 mm column of microporasil A eluting with methyl tert-butyl ether:hexanes (1:9) and using u.v.
detection at 220 nm. The isomer (lS,2S,3R,5S)-pinanediol l-(1,1-dimethyl-ethoxycarbonyl)-pyrrolidine-2S-boronate eluted first under these con~itions.
S-isomer: lH NMR (C6D63: ~ 0.55 (s, 3 H), 1.09 (s, 3 H), 1.52 (s, 9 H), 1.60 (s, 3 H), 1.2 - 2.2 (m, 8 H), 3.1 - 3.5 (m, 3 H), 4.11 tm, 0.3 H), 4.33 tm, 0.7 H); C NMR (C6D6): 6 23.9, 26.6, 27.1, 27.3, 28.4, 28.6, 28.8, 36.0, 38.2, 39.9, 46.1, Sl.9, ~-78.3, 78.5, 85.7, 154.9.
WO93/10127 PCT/~S92/~9~S
~123~28 22 R-isomer: lH NMR (C6D6): ~ 0.52 (s, 3 H), 1.08 -~
(s, 3 H), 1.52 (s, 9 H), 1.61 ~s, 3 H), 1.2 - 2.2 (m, 8 H), 3.1 - 3.6 (m, 3 H), 4.01 (m, 0.3 H), 4.25 (m, 0.7 H~; 13C NMR (C6D6) 23.9, 26.6, 27.1, 27.3, 28.4, 28.7, 28.9, 35.8, 38.2, 39.6, 46.2, 51.B, 78.1, 78.5, 85.7, 154.5.
It will be recognized that ~lR,2R,3S,5R)-pinanediol-l-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2S-borona~e and (lR,2R,3S,5R)-pinanediol-~-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2R-boronate could be produced in an analogous manner, starting with (lR,2R,3S,5R)-(-)-pinanediol.
Example_4 -~
rlS.2S.3R~5S)-Pinanediol ~yrrolidine-2S-boronate ~-hvdrochloride A solution of (lS,~S,3R,5S)-pinanediol- -1-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2S-boronate, produced as in Example 3 (28.5 mg, 0.08 mmol) was stirred in a solution of dry HCl in EtOAc (approximately 3M). After 2 h the solution was concentrated twice from EtOAc to produce 21.2 mg (91~) of the desired hydrochloride as a white solid (mp 204C (dec)).
1H NMR (CDCl3): ~ 0.83 (s, 3 H), 1.14 (d, J =
llHz, 1 H), 1.29 (s, 3 H), 1.45 (s, 3 H), 1.85 - 2.15 ~m, 6 H), 2.17 - 2.50 (m, 3 H), 3.18-3.25 (m, 1 H), 3.45 (bs, 2 H~, 4.42 (dd, J = 1.8, 8.6Hz, 1 H), 8.80 WO93/10127 P~T/US~2/09~S
. . ~., 2123l28 (bs, lH~, 10.56 (bs, lH); C NMR (CDC13): ~
23.9, 24.5, 26.5, 27.0, 27.2, 28.4, 34.9, 38.2, 39.4, 45.8, 51.2, 79.0, 87.6; CIMS m/z (~ rel int) 250 (MH+, 100); HRMS (EI) for C14H24BNO calcd 249.1900, found ~49.1899.
It will be recognized that (lR,2R,3S,5R)-pinanediol- ~
pyrrolidine-2S-boronate hydrochloride could be made in ~;-an analogous manner.
Example 5 (lS 2S 3R,5S)-Pinanediol pyrrolidine-2R-boronate hy~rochloride A solution of ~lS,2S,3R,5S)-pinanediol-l-(l,l-dimethylethoxycarbonyl)-pyrrolidine-2R-boronate, produced as in Example 3 (18.3 mg, 0.05 mmol) was treated with dry HCl in EtOAc as above. Work~up produced 14.3 mg (96~) of the desired hydrochloride as a white solid (mp 248 oC (dec)).
1H NMR (CDC13): ~ 0.83 (s, 3 H), 1.14 (d, J =
llHz, 1 H), 1.29 (s, 3 H~, 1.45 (s, 3 H), 1.85 - 2.15 (m, 6 H), 2.17 - 2.50 (m, 3 H), 3.18-3.25 (m, 1 H), 3.45 (bs, 2 H), 4.42 (dd, J = 1.8, 8.6Hz, 1 H), 8.80 (bs, 1 H), 10.56 (bs, 1 H); 13C NMR (CDCl ~ ~
23.9, 24.5, 26.5, 27.0, 27.2, 28.S, 34.9, 38.1, 39.4, 45.8, 51.2, 79.0, 87.8; CIMS m/z (% rel int) 250 (MH~, 100); HRMS (EI) for C14H24BN02 calcd 249.1900, found 249.1903.
WO 93~10127 PCI`/USg2/Og845 -212312~
It will be recognized that (lR,2R,3S,5R)-pinanediol pyrrolidine-2R-boronate hydrochloride could be made in an analogous manner.
Example 6 (lS~2S~3R,5s)-Pinanediol dimethylethoxvcarbonvl)-pyrrole-2-boronate A solution of 1-(1,1-dimethylethoxycarbonyl)-pyrrole-2-boronic acid, produced as in Example (1.36 g, 6.45 mmol) and (lS,2S,3R,5S)-(+)-pinanediol (1.10 g, 6.45 mmol) was stirred in 20 mL of ether for 4 h. Rotary evaporation followed by flash chromatography over silica gel (95:5 hexane:EtOAc) `~
produced 1.83 g (82%) of the desired product as a clear oil.
H NM~ (CDC13): ~ 0.90 (s, 3 H), 1-30 (s, 3 H~, 1.41 (dj J = 11 Hz, 1 H), 1.50 (s, 3 H), 1.50 (s, 3 H), 1.59 (s, 9 H), 1.96 (m, 2 H), 2.21 (t, J = 6Hz, 1 H3, 2.16 - 2.40 (m, 2 H), 4.45 (dd, J = 2, 8Hz, 1 H), ~;
6.20 (t, J = 3Hz, 1 H), 6.65 (d, J = 3Hz, 1 H), 7.40 (d, J = 3Hz, 1 H); 13C NMR (CDC13): ~ 24.0, 26.4, 27.2, 28.1, 28.6, 35.5, 38.3, 39.8, 51.8, 79.8, 83.6, 83.9, 111.6, 123.2, 124.7, 150.0; CIMS m/z (%
rel int) 346 (MH+, 4), 246 (81), 153 (100), 135 (56).
It will be recognized that (lR,2R,3S,5R)-pinanediol-1-(1,1-dilnethylethoxycarbonyl)-pyrrole-2-boronate could be made in an analogous manner.
WO93/10127 PCT/US92~0~5 . ~ .
2123:~28 Example 7 -~ DimethYlethoxvcarbonyl~-PYrrolidine-2-boronic acid from 1~ dimethylethoxvcarbonyl)-pYrrolidine To a solution of 1-(1,1-dimethylethoxycarbonyl)-pyrrolidine (17.1 g, 100 mmol) in diethyl ether (200 mL) at -78 C under an atmosphere of nitrogen was added 1.3M sec-butyllithium in cyclohexane (92.3 mL, 120 mmol) whilst maintaining the temperature below -60 C. After addition was complete, the reaction mixture was stirred at -7~ C for 4 h.
Trimethylborate (31.1 g, 300 mmol) was added and the mixture was allowed to warm to room temperature over 3h; After an additional 12h, water (150 mL) was added followed by 2M NaOH (200 mL~. The aqueous phase was isolated and the organic phase was reextracted with 2M
NaOH (150 mL). The combined basic extracts were acidified to pH 3 using 2M HCl and extracted using EtOAc (5 x 200 mL). The combined organic extracts were dried (Na2SO4) and concentrated to afford the desired product as a white crystalline solid (15.49g, 72%), identical with the material produced in Example Example 8 flS,2S,3R,5S)-Pinanediol 1-(1 1-dimethYlethoxycarbonvl)-pyrrolidine-2RS-boronate To a stirred solution of the material obtained in Example 7 (15.49 g, 72.0 mmol) in chloroform (250 mL) was added (lS,2S,3R,5S)-(+)-pinanediol (12.77 g, WO93/10127 PCT/US~2/09~5 21~31~ 26 75 mmol~. After stirring at room temperature under a nitrogen atmosphere for 16 h, the solvent was removed and the residue purified via flash chromatography over silica gel (hexane/EtOAc 9:1, 4:1) to give the desired product as a 1:1 mixture of diastereomers as an oil (23.62 g, 67.7% based on l-(l,1-dimethyl-ethoxycarbonyl)-pyrrolidine). This was identical with ~-the mixture of isomers produced in Example 3.
H NMR (CDCl3): ~ 0.85 (s, 3H), 1.12-1.21 (m, lH), 1.29 (s, 3H), 1.41 (s, 3H), 1.45 (s, 9H), 1.81-2.20 (m, 8H~, 2.28-2.39 ~m, lH), 3.04-3.18 (m, lH), 3.34-3.45 ~m, 2H), 4.28-4.38 (m, lH); 13C NMR
(CDCl3): ~ 23.7, 26.2, 27.1, 28.5, 35.5, 38.2, 39;6, 46.1, 78.0, 78.8, 85.7, 85.8, 154.7; CIMS m/z (~
rel int) 350 (MH+j 100), 294 (72), 250 (30).
ExamPle g Analvtical Method for the Diastereoisomers of (lS 2S,3R,5S)-Pinanediol PYrrolidine-2-boronate hydrochloride.
A reagent solution of Q.2 M phenyl isothiocyanate in dichloromethane-triethylamine (9:1~ was prepared. The sample to be analyzed (1-5 mg) was treated with 10 ~L of the reagent solution per ~mole of analyte and the clear solution was allowed to stand at room temperature for 15 min. A 1 ~L sample of the solution was then diluted in 1.00 mL of HPLC-grade acetonitrile and 10 ~L of this solution was analyzed by ~PLC (column: YMC AQ-303 S-5 120A, 4.6 x 250 mm;
WO93/10127 PCT/US92/09~5 - ~12~ l ~8 mobile phase: 65% MeCN - 35~ 25 mM ammonium phosphate, pH 7.5; flow rate l mL/min; detection by W at 254 nm). The phenylthiourea derivative of the R isomer of proline boronic acid elutes at about 6.4 min, its epimer elutes at about 7.8 min, and unreacted phenyl isothiocyanate, which serves as an internal standard, elutes at 12.2 min. .
Example 10 (ls~2s~3R~ssL~pinanediol p~rrolidine-2RS-boronate hvdrochloride A stirred solution of ~lS,2S,3R,5S)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2RS-boronate ~224 g, 0.64 mol) in diethyl ether (900 mL) was cooled in ice and dry HCl gas passed into the solution for 35 min at 10-18 C. The solution was stirred at room temperature overnight, cooled again in ice and the precipitate filtered off. The solid was washed with cold ether (400 mL) followed by petroleum ether/diethyl ether 9:1 (200 mL~ and dried under ~acuum to give the desired hydrochloride as a white solid (113 g, 62~) (mp 228-234C). Analysis of this material by HPLC as described in Example 9 showed it to be a 60:40 mixture of R:S isomers of the boronic acid.
WOg3~1~127 PCT/US92/09~5 212~1~8 1H NMR ~CDC13): ~ 0.83 (s, 3 H), 1.14 (d, J =
llHz, 1 H), 1.29 (s, 3 H), 1.45 (s, 3 H), 1.85 - 2.15 (m, 6 H), 2.17 - 2.50 (m, 3 H), 3.18-3.25 (m, 1 H), 3.45 (bs, 2 H), 4.42 (dd, J = 1.8, 8.6Hz, 1 H), 8~0 (bs, 1 H), 10.56 (bs, 1 H); C NMR lCDCi3) 23.9, 24.5, 26.5, 27.0, 27.2, 28.4, 34.9, 38.2, 39.4, 45.8, 51.2, 79.0, 87.6r CIMS m/z (% rel int) 250 (MH~, 100); Anal. Calcd for C14H24BNO2. HCl: C, 58.87, H, 8.B2, N, 4.90, Cl, 12.41. Found: C, 58.40,~
H, 8.86, N, 4.81, Cl, 12.39.
A similar reaction on a 29 g, 101 mmol scale using ethereal HCl (approx. 4.5M, 200 mL~ and EtOAc (150 mL) as solvent yielded the hydrochloride (11.1 g, 47%) as a B1:19-mixture of R:S isomers Example 11 -. :
(lS,2S,3R~ inanediol Pvrrolidine-2R-boronate hYdrochloride bY fractional crvstallization.
~ ' Method ~: ;
The 60:40 isomeric mixture obtained in Example 10 `
(1.18 g 4.13 mmol) was dissolved in CH2C12 (65 mL) with slight warming, and the solution filtered. The filtrate was diluted with EtOAc (65 mL) and crystallization began within a minute. The suspension was stirred for 1-2 h at room temperature and the first crop of solid was collected and the ;~- diastereomeric ratio determined as described in Example 9 (540 mg, 46%, R:S ratio 97.1:2.9). Solvent WO~3~0127 PCT/US92/09 was distilled from the filtrate until most of the CH2C12 was removed, then the residual EtOAc solution was stirred at room temperature overnight to afford a second crop of off-white solid (346 mg, 29~, R:S ratio 39.2:60.8). The first crop was recrystallized from isopropyl alcohol (10 mL) to afford 430 mg (80%
recovery) of material >99% 2-R isomer. (mp 269-272 C
(dec)) ~]25D +0~70O (c=1.15, MeOH) H NMR ~CDC13): ~ 0.83 (s, 3 H), 1.14 (d, J =
llHz, 1 H), 1.29 (s, 3 H), 1.45 (s, 3 H), 1.85 - 2.15 (m, 6 H), 2.17 - 2.50 (m, 3 H), 3.18-3.25 (m, 1 H), 3.45 ~bs, 2 H), 4.42 (dd, J = 1.8, 8.5Hz, 1 H), 8.80 (bs, 1 H), 10.56 (bs, 1 H); l C NMR (CDC13) ~
23;9, 24.5, 26.5, 27.0, ~7.2, 28.5, 34.9, 38.1, 39.4, 45.8, 51.2, 79.0, 87.8; CIMS m/z (% rel int) 250 (MH+, 100); Anal. Calcd for C14H~4BN~2. HCl: C, 58.87, H, 8.82, N, 4.90, Cl, 12.41. Found: C, 58.64, H, ~.79, N, 4.90, Cl, 12.66.
Method B:
r A suspension of (lS,2S,3R,5S)-pinanediol-pyrrolidine-2RS-boronate hydrochloride as a 1:1 mixture of isomers (850 mg, 2.98 mmol) in EtOAc (60 mL) was heated under reflux with stirring for 4 h. The mixture was filtered hot and the collected solid dried to give material enriched in the R isomer (541 mg 64%~, R:S ratio 2:1. Evaporation of the filtrate yielded material enriched in the S isomer ~217 mg), R:S = 1:4. The filtered solid (500 mg) was treated in the same way with EtOAc (45 mL) for 1.5 h and again filtered hot to yield a solid (366 mg, 73%), R:S = 7:1. This material was again treated with EtOAc ~V093/10127 PCT/US92~0~5 ', ,, ~123~2~ :~
(38 mL) for 1.5 h. The solid isolated (287 mg, 78%) now had R:S ratio 97:3. The spectral properties were the same as those of material obtained by method A.
'':
Example 12 - ~-1-(l,i-DimethylethoxycarbonYl)-pyrrolidine-2-boronic acid from (lS,2S,3R,5S) pinanediol 1-(1,l-dimethylethox~carbonYl)-Pyrrolidine-2-boronate To a solution of (lS,2S,3R,5S)-pinanediol-~ dimethylethoxycarbonyl)-pyrrolidine-2RS-boronate ~-from Example 8 (1.9 g, S.44 mmol) in acetone (80 mL) wa~ added O.lM ammonium acetate solution (80 mL) and sodium metaperiodate (3.49 g,16.33 mmol). The reaction mixture was stirred at room temperature for 40 h, then the acetone was evaporated and the residue was treated with 2M NaOH solution. This a~ueous phase ;
was washed with CH2C12 (2 x 80 mL), acidified with 2M HCl to pH 3 and extracted with CH2C12 (4 x 80 mL). The combined organic extracts were dried (Na2S04) and concentrated to afford the desired product as a white foamy solid (890 mg, 76%), identical by NMR with the material prepared in Example ~;
2. The boronic acid was derivatized with pinacol for purposes of analysis.
' W O 93/10127 P(~r/US92/09845 ~1231 2~
Example 13 Pinacol ~ dimethYlethoxycarbonyl)- :
Pyrrolidine-2Rs-boronate To a stirred solution of the boronic acid from Example 12 (890 mg, 4.14 mmol) in chloroform was added pinacol (489 mg, 4.14 mmol). After stirring for 16h at room temperature, the solvent was removed and the residue was purified via chromatography over silica gel (hexane/EtOAc, 4:1) to give the desired product as a white solid (1.04 g, 85%) (mp 73-75 C).
H NMR (CDCl3): ~ 1.18 (s, 6H), 1.21 (s, 6H), 1.38 ~s, 9H), 1.5.-2.00 (m, 4H), 2.9$ (br s, lH), 3.27 (m, 2H~; 13C NMR (CDCl3): ~ 24.3, 24.5, 24.7, 24.~, 25.3, 27.0~ 27.6, 28.4, 2~.6, 43.6, 45.8, 46.3, 78~8, 83.2, 154.4, 154.8; CIMS m/z (% rel int) 29~
(18), 242 (100, MH+ - tBu), 198 (30, MH+ - Boc); Anal.
Calcd for C15H28BNO4: C, 60.62, H,9.50, N, 4.71.
Found: C, 60.94, H, 9.65, N, 4.88.
ExamPle 14 N~ DimetbvlethoxYcarbonYl)-L-valvlpyrrolidine-2R-boronate (lS 2S 3R 5S)-Pinanediol ester A solution of t-BOC-L-Valine (351.7 g, 1.62 mol) in CH2Cl2 (1.6 L) was cooled with an ice bath and a solution of dicyclohexylcarbodiimide (161.8 g, 0.784 mol) in CH2C12 (0.75 L) was added within 40 min at 0-2 C. After addition the solution was WO~3/10127 PCT/US92/09~5 `
; ; ~
stirred for 3.5 h at 0-5 C. The white precipitate was filtered off and washed with CH2Cl2 (0.2 L). The resulting clear solution was added at 18-20 C
(waterbath cooling) to a solution of -~
(lS,2S,3R,5S)-pinanediol pyrrolidine-2RS-boronate hydrochloride (210 g, 0.73S mol), prepared as in Example lO, in CH2Cl2 (2.0 L) containing N-methylmorpholine (164 g, 1.62 mol). The mixture was allowed to stir at~room temperature overnight. The cloudy solution was filtered through a 16 cm dia. x 2 cm high bed of silica gel (200-425 mesh) and washed wlth CH2Cl2 (1.5 ~). The solvent was evaporated to yield a highly viscous oil (542 g). This oil was dissolved in ethyl acetate (0.7 L~ and the mixture cooled in an ice bath. Crystals formed, which were filtered off at low temperature, and washed with cold ethyl acetate (0.1 L). The wet filter cake was transferred into petroleum ether (0.65 L) and stirred at room temperature for 1 h. The white solid was filtered, washed with cold petroleum ether (0.1 L), and dried to constant weight to yield the title compound as a white solid ~113.4 g) (mp 128-13~ C).
ll the mother Iiquors were combined and concentrated to a volume of approx. 0.8 L. After standing for 2 days in the freezer a solid formed, which was filtered off, and treated with petroleum ether as above to yield a beige solid (50.4 g). This was a mixture of impurities and the unwanted diastereoisomer. The mother liquor from above was concentrated and the residue purified over a silica gel column (14 cm dia.
x 60cm) using héxane/ethyl acetate (85:15) (14 L). ~;
Appropriate fractions were collected, treated with -petroleum ether, the solid collected by filtration and f ';
WO93/10~27 P~T/US92/~9845 .....
~,~
212312~
dried, to yield more desired product ~18.5 g). The other diastereoisomer was also obtained (7.5 g) (mp 82-83 C). A second column was performed on the combined mixed fractions and mother li~uors to yield additional pure compound (13.5 g), total combined yield 145.4 g t44.3%) of desired diastereoisomer (mp 128-130 C).
H NMR (CDCl3): ~ 0.83 (s, 3 H), 0.91 (d, J =
6.7Hz, 3 H), 0.97 (d, J = 6.7Hz, 3 H), 1.27 (s, 3 H), 1.35-1~45 (m, 1 H), 1.39 (s, 3 H), 1.41 (s, 9 H), 1.72-2.14 (m, 9 H), 2.26-2.36 (m, 1 H), 3.15 (dd, J =
6.7, lO.lHz, 1 H), 3.43-3.51 (m, 1 H), 3.70-3.81 (m, l H), 4.19-4.28 tm, 2 H), 5.29 (d, J - 9.2~z, 1 H);
3~C NMR (CDCl3): ~ 17.3, 19.2, 24.0, 26.3, 27.1 27.2, 27.4, 28.4, 28.6, 31.4, 33.9, 35.5, 38.2, 39.6, 46.7, 51.2, 56.6, 77.8, 79.2, 85.8, 155.9, 170.2; CIMS
m/z (~ rel int) 449 ~MH~, 100), 393 (50); Anal. Calcd for C24H41BN2O~: C, 64.28, H, 9.22, N, 6.25.
Found: C, 64.58, H, 9.33, N, 6.52.
- ....
Example 15 L-valylpyrrolidine-2R-boronate (lS,2S,3R 5S)-pinanediol ester hydroqen maleate N-(1,1-Dimethylethoxycarbonyl)-L-valylpyrrolidine-2~-boronate (lS,2S,3R,5S)-pinanediol ester (248 mg, 0.553 mmol) was added to a stirred solution of dry hydrogen chloride in ethyl acetate. After 1.5 h the solvent was evaporated to leave the deprotected hydrochloride. The residue was partitioned between ' WO~3~10127 P~T/US92/0984~
212~128 34 CH2Cl2 and sodium carbonate solution, and the organic layer dried over magnesium sulfate. The organic layer contains the free base of the title compound, which exists as a cyclic form containing a nitrogen-boron bond, but reverts to the open form on adding acid. The organic solution was filtered into a solution of maleic acid (64 mg, 0.553 mmol) in methanol ~5 mL), and the solvent evaporated to leave a crystalline residue (258 mg), ~hich was recrystallized from ethyl acetate to give the title compound ~193 mg, 75%) (mp 145-146 C).
- H NMR ~CDCl3): ~ 0.84 (s, 3 H), 1-08 ~d, J =
6~9Hz, 3 H), 1.13 (d, J = 6.9Hz, 3 H), 1.26-1.31 (m, 2 H), 1.23 (s, 3 H), 1.38 ~s, 3 H), 1.72-2.15 (m, 7 H), 2.2~-2.38 (m, 2 H), 3.28 (dd, J = 6.9, 9.4 Hz, 1 H), 3.38-3.47 (m, 1 H), 3.73-3.78 (m, 1 H), 4.14 (d, J = 5.1Hz, 1 H), 4.26 (d, J = 7.1Hz, 1 H), 6.25 (s, 2 H), 7.5-9.0 (v. br, 4 H); C NMR (CDCl3): ~ ~
17.0, 18.4, 24.0, 26.3, 27.0, 27.1, 28.7, 30.0, 35.4, -38.2, 39.5, ~7.3, 51.2, 56.6, 78.1, 86.2, 135.5, 166.3, 169.5; CIMS m/z (% rel int) 349 (MH+, 100), 197 (18); Anal. Calcd for C23H37BN207: C, 59.49, : H, 8.03, N, 6.03. Found: C, 59.50, H, 8.13, N, 6.03.
.
.
WO9~/10127 ~CT/US92/09~5 Example 16 L-valYlpvrrolidine-2R-boronic acid methanesulfonate a) cyclo-L-valylpyrrolidine-2R-boronic acid ~
A solution of the maleate salt obtained in Example 15 -(5.0 g, 10.8 mmol) in dilute acetic acid (1.0%, 60 mL) was loaded on to a column (3.5 cm deep x 4 cm dia.) of Dowex 50X2-200 ion exchange resin in the H+ form. The .
column was then eluted with acetic acid (1.0%, 14 L~, water (42 L) and ammonium hydroxide solution (1:100 dilution of commercial 0.880 solution). Pinanediol could be recovered from the neutral and acidic : fractions. The product was found in early basic fractions, which were collected and washed with CH2Cl2 (2 x 100 mL). The organic extracts were dried and concentrated to afford recovered free base of thP starting material (741 mg, 20%), along with some pinanediol. The aqueous phase was lyophilized to afford the title compound, which exists in a cyclic .
form with a nitrogen-boron bond, as a white solid (1.52g, 66%) (mp 120-130C). -, : H NMR (D20) ~ 0 97 (d, J = 7.0 Hz, 3 H), 1.06 (d, J = 7.0 Hz, 3 H), 1.59-1.80 (m, 2 H), 1.95-2.03 : (m, 2 H), 2.41-2.51 (m, 1 H), 2.62-2.69 (m, 1 H), 3.23-3.32 (m, 1 H), 3.Sl-3.58 (m with overlapping doublet, J = 4.2 Hz, 2 H); 13C NMR (D20): ~
19.0, 21.7, 27.3, 30.7, 29.9, 49.6, 61.0, 170.3; IR
(cm 1) 3400-3314, 3221-3108, 2961-2872, 1637, 1452-1369; CIMS m/z (~ rel int) 375 (9o, WO93~0127 PCT/US92/09845 2 1 ~ 8 M2H+-3H20), 197 (100, MH+-H20)i Anal. Calcd for C9HlgBN203: C, 50.50, H~ 8.95~ N, 13-09-Found: C, 50.43, H, 8~76, N, 12.93.
b) L-valylpyrrolidine-2R-boronic acid methanesulfonate To a stirred suspension of the cyclized boronic acid obtained above (5.17 g, 24.16 mmol) in acetonitrile (190 mL) under nitrogen was added a solution of ' ~:
methanesulfonic acid (2.32 g, 24.16 mmol) in `.
acetonitrile (10 mL) dropwise over five minutes and the mixture stirred at room temperature for 2 h. The ~;
solid was collected by filtration, washed well with acetonitrile and diethyl ether and dried to afford the title compound as a white solid (6.14g, 82%) (mp 179-180 C). Crystallization of this ~aterial from dimethylformamide/acetonitrile ga~e a 70~ recovery of material in a single crop (mp 181-182 C).
- ;
H NMR (D20, phosphate, pH2): ~ 0.99 (d, J = 6.8 Hz, 3H), 1.09 (d, J = 6.9Hz, 3H), 1.69-1.75 (m' lH), 1.90-1.99 (m, lH), 2.10-2.14 (m, 2H), 2.28-2.35 ~m, lH), 2.80 (s, 3H), 3.07 (dd, J = 7.0 and 11.2 Hz, lH), 3.46-3.51 (m, lH), 3.75 ~t, J = 9.0 Hz, lH), 4.14 (d, J = 5.1 Hz, lH); the cis amide rotamer (ca. 3%) is also observed at 3.53-3.55 (m) and 3.83 (d, J =
6.2 Hz); 13C NMR: ~ 16.2, 18.4, 26.9, 27.1, 29.0, 38.8, 47.9, 49.0, 57.2, 167.2; peaks due to the cis amide rotamer are observed at 16.8, 24.3, 29.9, 57.8, -167.5; IR (cm ) 3387, 3000 (br~, 2972, 2655, 1646, 1370, 1197; CIMS m/z (% rel int, ethylene glycol adduct) 241 (MH+ 100); Anal. Calcd for C1oH23BN206S: C, 38.72, H, 7.47, N, 9.03.
Found: C,38.65, H, 7.45, N, 8.44.
Exam~le 17 N~ DimethvlethoxycarbonYl)-L-valylPvrrolidine-2R-boronic acid .
To a stirred solution of N-(l,l-dimethyl-ethoxycarbonyl)-L-valylpyrrolidine-2R-boronate ~lS,2S,3R,SS)-pinanediol ester, prepared as in Example 14, (1.0 g, 2.3 mmol) in acetone (75 mL) was added ammonium acetate solution (60 ml, 0.1 M) and sodium metaperiodate (1.48 g, 6.91 mmol). The reaction mixture was stirred at room temperature for 48 h, then the acetone was evaporated. The residue was treated with 2M sodium hydroxide solution (100 mL), and washed with CH2Cl2 (2 x 50 mL). The aqueou~ layer was carefully acidified with 2M hydrochloric acid to pH 3 and extracted with CH2Cl2 (4 x 70 mL). The combined organic extracts of the acid solution were dried over sodium sulphate and concentrated to afford the desired product as a white ~oamy solid (700mg, 97%). Further purification vi~ chromatography over silica gel (CH2Cl2/methanol, 9:1) gave the boronic acid again as a white solid (449 mg, 62%) (mp 82-92C).
H NMR (CDCl3~: ~ 0.95 (d, J = 5.7 Hz, 6H), 1.42 (s, 9H), 1.55-1.80 (m, lH) 1.80-2.20 (m, 4H), 2.89-3.07 (m, lH), 3.30-3.55 (m, lH), 3.55-3.65 (m, :
lH), 4.10-4.30 (m, lH), 5.34 (d, J = 9 2 Hz, lH);
1 C NMR (~DCl3): ~ 18.0, 19.1, 26.3, 27.7, 28.3, 31.2, 46.1, 52.0, 55.7, 79.5, lS5.6, 170.8; IR
(cm 1) 3395-3319, 2971-2875, 1711, 1619, 1400, 1174;
CIMS m/z (% rel int, ethylene glycol adduct) 341(MH , 100), 285(MH -tBu, 67), 241(MH -BOC, 21).
WO93/10127 PCT/~S92/09~5 .
Exam~le 18 L-valYlp~rrolidine-2R-boronic acid hydrochloride N-(1,1-Dimethylethoxycarbonyl)-L-valylpyrrolidine-2R ~-boronic acid, obtained in Example 17 (250 mg, 0.796 mmol) was stirred with HCl/ether (4.5M, 20 mL) at room temperature under nitrogen for 1.5 h. The solvent was then evaporated and the residue triturated with diethyl ether (3 x 10 mL) and each time the ether was decanted. The residue was dried to yield the title compound as a white powdery solid (172 mg, 86%) (mp 211-213C).
lH`NMR ~D2O, phosphate pH 2): ~ 0.99 (d, J = -~
6.9 Hz, 3 H), 1.09 (d, J = 7.0 Hz, 3 H), 1.67-1.76 (m, 1 H), 1.87-2.01 ~m, 1 H), 2.09-2.15 (m, 2 H), .~:
.28-2.35 (m, 1 H), 3.07 (dd, J = 7.0 and 11.4 Hz, 1 H), 3.48 (dt, 3 = 6.7 and 10.3 Hz, 1 H), 3.73 (dt, J = 1.7 and 10.2 Hz, 1 H), 4.14 (d, J = 5.2 Hz, 1 H);
3C NMR: ~ 16.0, 18.3, 26.9, 27.1, 28.9, 47.9, .
48.9, 57.2, 167.3; IR (cm ) 3400-2800, 3368, 2970l2880, 1635, 1475-1378, 1400; CIMS m/z (% rel int, e~hylene glycol adduct) 241 (MH , 100).
' WOg3~10127 PC~/US92/09 .
xample 19 2123128 cyclo-L-Valvlpyrrolidine-2R-boronic acid by transesterification with ~henylboronic acid A solution of L-valylpyrrolidine-2R-boronate -(lS,2S,3R,5S~-pinanediol ester hydrochloride, prepared -as in Example 15 ~500 mg, 1.3 mmol) in lM hydrochloric acid (10 mL) containing hexane (20 mL) and phenylboronic acid (500 mg, 2.6 mmol) was stirred vigorously for lh at room temperature. The hexane was removed by decantation, then more hexane (20 ml~ was added and the mixture stirred for a further 30 min.
The layers were separated and the combined hexane l~yers dried over sodium sulphate and concentrated to give pinanediol phenylboronate (331 mg, 99%) as a ..
white crystalline solid. The aqueous layer was then passed through a column of Dowex 50 ion exchange resin. The column was eluted with water (200 mL), followed by ammonium hydroxide solution (1:100 dilution of commercial 0.880 solution, 50 ml).
Isolation of the basic fractions followed by lyophilization gave the free boronic acid (230 mg, 83~) as a white powder, identical by NMR with the material obtained in Example 16a.
.
. .
Claims (44)
1. A method for making a prolineboronic acid ester of the formula VII
(VII) wherein X is a linking group, which method comprises:
a) treating pyrrole with an activated derivative of carbonic acid, to yield an N-protected pyrrole of the formula I
(I) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl, b) treating the protected intermediate of the formula I with a lithiating agent, to yield an intermediate of the formula II
(II) wherein R is as defined above, c) reacting the intermediate of formula II with a trialkyl borate, wherein each alkyl group may be straight, branched or cyclic and contains 1 to 6 carbon atoms, followed by acid catalyzed hydrolysis, to yield an intermediate of the formula III
(III) wherein R is as defined above, d) reducing the compound of formula III, using catalytic hydrogenation, in order to yield the proline intermediate of formula IV
(IV) wherein R is as defined above, e) reacting the compound of formula IV with a diol of the formula V, HO-X-OH (V) wherein X is the same linking group mentioned above, to yield a boronate ester of the formula VI
(VI) wherein X is the same linking group mentioned above and R is as defined above, and f) removing the protecting group from the nitrogen atom in the proline ring.
(VII) wherein X is a linking group, which method comprises:
a) treating pyrrole with an activated derivative of carbonic acid, to yield an N-protected pyrrole of the formula I
(I) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl, b) treating the protected intermediate of the formula I with a lithiating agent, to yield an intermediate of the formula II
(II) wherein R is as defined above, c) reacting the intermediate of formula II with a trialkyl borate, wherein each alkyl group may be straight, branched or cyclic and contains 1 to 6 carbon atoms, followed by acid catalyzed hydrolysis, to yield an intermediate of the formula III
(III) wherein R is as defined above, d) reducing the compound of formula III, using catalytic hydrogenation, in order to yield the proline intermediate of formula IV
(IV) wherein R is as defined above, e) reacting the compound of formula IV with a diol of the formula V, HO-X-OH (V) wherein X is the same linking group mentioned above, to yield a boronate ester of the formula VI
(VI) wherein X is the same linking group mentioned above and R is as defined above, and f) removing the protecting group from the nitrogen atom in the proline ring.
2. The method of claim l wherein, in step (c), the intermediate of formula II is reacted with trimethyl or triethyl borate.
3. The method of claim 1, wherein the linking group X is a saturated 2- to 3-membered hydrocarbon chain; a saturated 2- to 3-membered hydrocarbon chain which constitutes part of a C5-12 carbocyclic system which may optionally contain unsaturations or ring fusions; a 2- to 3-membered hydrocarbon chain which constitutes part of an aromatic ring system; or, X is a group of the formula -(CH2)n-NH-(CH2)m-, wherein n and m are each 2 or 3; wherein such groups may be unsubstituted or substituted by one or more C1-3alkyl or phenyl groups.
4. The method of claim 1 wherein the esterification in step (e) is carried out with a diol selected from the group consisting of ethylene glycol, pinacol, catechol, pinanediol, butan-2,3-diol, diethanolamine, and 1,2-diphenylethan-1,2-diol.
5. The method of claim 4 wherein the diol is optically active pinanediol.
6. The method of claim 5, wherein the N-protected pinanediol ester formed in step (e) of claim 1 is further separated into its diastereoisomers.
7. The method of claim 5, wherein the N-deprotected pinanediol ester formed in step (f) of claim 1 is further separated into its diastereoisomers.
8. The method of claim 1, wherein R is tert-butyl, benzyl, trimethylsilylethyl, phenyl, methyl, or ethyl.
9. A method for making a prolineboronic acid ester of the formula VII
(VII) wherein X is a linking group which method comprises:
a) treating pyrrole with an activated derivative of carbonic acid, to yield an N-protected pyrrole of the formula I
(I) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl, b) treating the protected intermediate of the formula I with a lithiating agent, to yield an intermediate of the formula II
(II) wherein R is as defined above, c) reacting the intermediate of formula II with a trialkyl borate, wherein each alkyl group may be straight, branched or cyclic and contains 1 to 6 carbon atoms, followed by acid catalyzed hydrolysis, to yield an intermediate of the formula III
(III) wherein R is as defined above, d) reacting the compound of formula III with a diol of the formula V, HO-X-OH (V) wherein X is a linking group, to yield a boronate ester of the formula IIIA
(IIIA) wherein R is as defined above, e) reducing the resulting ester, using catalytic hydrogenation, to yield the proline intermediate of formula VI
(VI) and f) removing the protecting group from the nitrogen atom in the proline ring.
(VII) wherein X is a linking group which method comprises:
a) treating pyrrole with an activated derivative of carbonic acid, to yield an N-protected pyrrole of the formula I
(I) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl, b) treating the protected intermediate of the formula I with a lithiating agent, to yield an intermediate of the formula II
(II) wherein R is as defined above, c) reacting the intermediate of formula II with a trialkyl borate, wherein each alkyl group may be straight, branched or cyclic and contains 1 to 6 carbon atoms, followed by acid catalyzed hydrolysis, to yield an intermediate of the formula III
(III) wherein R is as defined above, d) reacting the compound of formula III with a diol of the formula V, HO-X-OH (V) wherein X is a linking group, to yield a boronate ester of the formula IIIA
(IIIA) wherein R is as defined above, e) reducing the resulting ester, using catalytic hydrogenation, to yield the proline intermediate of formula VI
(VI) and f) removing the protecting group from the nitrogen atom in the proline ring.
10. The method of claim 9 wherein, in step (c), the intermediate of formula II is reacted with trimethyl or triethyl borate.
11. The method of claim 9, wherein the linking group X is a saturated 2- to 3-membered hydrocarbon chain; a saturated 2- to 3-membered hydrocarbon chain which constitutes part of a C5-12 carbocyclic system which may optionally contain unsaturations or ring fusions; a 2- to 3-membered hydrocarbon chain which constitutes part of an aromatic ring system; or, X is a group of the formula -(CH2)n-NH-(CH2)m-, wherein n and m are each 2 or 3; wherein such groups may be unsubstituted or substituted by one or more C1-3alkyl or phenyl groups.
12. The method of claim 9 wherein the esterification in step (d) is carried out with a diol selected from the group consisting of ethylene glycol, pinacol, catechol, pinanediol, butan-2,3-diol, diethanolamine, and 1,2-diphenylethan-1,2-diol.
13. The method of claim 12 wherein the diol is optically active pinanediol.
14. The method of claim 13, wherein the N-protected pinanediol ester formed in step (e) of claim 9 is further separated into its diastereoisomers.
15. The method of claim 13, wherein the N-deprotected pinanediol ester formed in step (f) of claim 9 is further separated into its diastereoisomers.
16. The method of claim 9, wherein R is tert-butyl, benzyl, trimethylsilylethyl, phenyl, methyl, or ethyl.
17. A method for making an intermediate of the formula IV
(IV) which method comprises:
a) treating pyrrole with an activated derivative of carbonic acid, to yield an N-protected pyrrole of the formula I
(I) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl, b) treating the protected intermediate of the formula I with a lithiating agent, to yield an intermediate of the formula II
(II) wherein R is as defined above, c) reacting the intermediate of formula II with a trialkyl borate, wherein each alkyl group may be straight, branched or cyclic and contains l to 6 carbon atoms, followed by acid catalyzed hydrolysis, to yield an intermediate of the formula III
(III) wherein R is as defined above, and, d) reducing the compound of formula III, using catalytic hydrogenation, in order to yield the proline intermediate of formula IV.
(IV) which method comprises:
a) treating pyrrole with an activated derivative of carbonic acid, to yield an N-protected pyrrole of the formula I
(I) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl, b) treating the protected intermediate of the formula I with a lithiating agent, to yield an intermediate of the formula II
(II) wherein R is as defined above, c) reacting the intermediate of formula II with a trialkyl borate, wherein each alkyl group may be straight, branched or cyclic and contains l to 6 carbon atoms, followed by acid catalyzed hydrolysis, to yield an intermediate of the formula III
(III) wherein R is as defined above, and, d) reducing the compound of formula III, using catalytic hydrogenation, in order to yield the proline intermediate of formula IV.
18. A method for making an intermediate of the formula IV
(IV) which method comprises:
a) treating pyrrolidine with an acylating agent, to yield a protected pyrrolidine of the formula VIII
(VIII) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl, b) treating the compound of formula VIII with a lithiating agent, to yield a compound of the formula IX
(IX) wherein R is as defined before, c) reacting the compound of formula IX with a trialkyl borate, wherein each alkyl group may be straight, branched or cyclic and may contain 1 to 6 carbon atoms, and d) hydrolyzing the product of the previous step, to yield the compound of formula IV.
(IV) which method comprises:
a) treating pyrrolidine with an acylating agent, to yield a protected pyrrolidine of the formula VIII
(VIII) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl, b) treating the compound of formula VIII with a lithiating agent, to yield a compound of the formula IX
(IX) wherein R is as defined before, c) reacting the compound of formula IX with a trialkyl borate, wherein each alkyl group may be straight, branched or cyclic and may contain 1 to 6 carbon atoms, and d) hydrolyzing the product of the previous step, to yield the compound of formula IV.
19. The method of claim 18 wherein, in step (c), the intermediate of formula IX is reacted with trimethyl or triethyl borate.
20. An intermediate of the formula III
(III) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl.
(III) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl.
21. 1-(1,1-Dimethylethoxycarbonyl)-pyrrole-2-boronic acid.
22. A compound selected from the group consisting of (1S,2S,3R,5S)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2S
boronate;
(1S,2S,3R,5S)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2R-boronate;
(1R,2R,3S,5R)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2S-boronate; and (lR,2R,3S,SR)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2R-boronate.
boronate;
(1S,2S,3R,5S)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2R-boronate;
(1R,2R,3S,5R)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2S-boronate; and (lR,2R,3S,SR)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrolidine-2R-boronate.
23. A compound selected from the group consisting of (1S,2S,3R,5S)-pinanediol pyrrolidine-2S-boronate hydrochloride; (1S,2S,3R,5S)-pinanediol pyrrolidine-2R-boronate hydrochloride;
(1R,2R,3S,5R)-pinanediol pyrrolidine-2S-boronate hydrochloride; (1R,2R,3S,5R)-pinanediol pyrrolidine-2R-boronate hydrochloride.
(1R,2R,3S,5R)-pinanediol pyrrolidine-2S-boronate hydrochloride; (1R,2R,3S,5R)-pinanediol pyrrolidine-2R-boronate hydrochloride.
24. A compound selected from the group consisting of (1S,2S,3R,5S)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrole-2-boronate;
and (1R,2R,3S,5R)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrole-2-boronate.
and (1R,2R,3S,5R)-pinanediol 1-(1,1-dimethylethoxycarbonyl)-pyrrole-2-boronate.
25. A method for removing pinanediol as the protective ester group from a boronate ester which method comprises treating such a boronate ester with an oxidizing agent which is capable of cleaving 1,2-diols.
26. The method of claim 25, wherein said oxidizing agent is sodium metaperiodate.
27. A method for removing pinanediol as the protective ester group from a compound of the formula X
(X) wherein R2 is a protecting group, and R3 is the side chain of a naturally occurring amino acid, optionally with appropriate protecting groups, or from a compound of the formula XI
(XI) wherein R3 is as defined above, which method comprises treating such a boronate ester with an oxidizing agent which is capable of cleaving 1,2-diols.
(X) wherein R2 is a protecting group, and R3 is the side chain of a naturally occurring amino acid, optionally with appropriate protecting groups, or from a compound of the formula XI
(XI) wherein R3 is as defined above, which method comprises treating such a boronate ester with an oxidizing agent which is capable of cleaving 1,2-diols.
28. The method of claim 27, wherein said oxidizing agent is sodium metaperiodate.
29. A method for removing pinanediol as the protective ester group from a boronate ester having a free amine group, which method comprises applying an aqueous solution of such boronate ester to a column of a cation exchange resin, eluting the column with water or dilute aqueous acid to remove the pinanediol, and finally eluting the column with dilute aqueous base to remove the free boronic acid product.
30. The method of claim 29, wherein said column material is a strongly acidic cation exchange resin.
31. A method for removing pinanediol as the protective ester group from a compound of the formula XI
(XI) wherein R3 is the side chain of a naturally occurring amino acid, optionally with appropriate protecting groups, which method comprises applying an aqueous solution of such a boronate ester to a column of a cation exchange resin, eluting the column with water or dilute aqueous acid to remove the pinanediol, and finally eluting the column with dilute aqueous base to remove the free boronic acid product.
(XI) wherein R3 is the side chain of a naturally occurring amino acid, optionally with appropriate protecting groups, which method comprises applying an aqueous solution of such a boronate ester to a column of a cation exchange resin, eluting the column with water or dilute aqueous acid to remove the pinanediol, and finally eluting the column with dilute aqueous base to remove the free boronic acid product.
32. The method of claim 31, wherein said column material is a strongly acidic cation exchange resin.
33. An intermediate of the formula X
(X) wherein the protecting group -O-X-O- is derived from pinanediol, and wherein R2 is a protecting group, and R3 is the side chain of a naturally occurring amino acid, optionally with appropriate protecting groups.
(X) wherein the protecting group -O-X-O- is derived from pinanediol, and wherein R2 is a protecting group, and R3 is the side chain of a naturally occurring amino acid, optionally with appropriate protecting groups.
34. N-(1,1-Dimethylethoxycarbonyl)-L-valylpyrrolidine-2R-boronate (1S,2S,3R,5S)-pinanediol ester.
35. An intermediate of the formula XI
(XI) wherein the protecting group -o-X-O- is derived from pinanediol, and wherein R3 is the side chain of a naturally occurring amino acid, optionally with appropriate protecting groups.
(XI) wherein the protecting group -o-X-O- is derived from pinanediol, and wherein R3 is the side chain of a naturally occurring amino acid, optionally with appropriate protecting groups.
36. L-Valylpyrrolidine-2R-boronate (1S,2S,3R,5S)-pinanediol ester or a salt thereof.
37. A method for making a prolineboronic acid ester of the formula VII
(VII) wherein X is a linking group, which method comprises:
a) treating pyrrolidine with an acylating agent, to yield a protected pyrrolidine of the formula VIII
(VIII) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl, b) treating the compound of formula VIII with a lithiating agent, to yield a compound of the formula IX
(IX) wherein R is as defined before, c) reacting the compound of formula IX with a trialkyl borate, wherein each alkyl group may be straight, branched or cyclic and may contain l to 6 carbon atoms, and d) hydrolyzing the product of the previous step, to yield a compound of the formula IV
(IV) e) reacting the compound of formula IV with a diol of the formula V, HO-X-OH (V) wherein X is the same linking group mentioned above, to yield a boronate ester of the formula VI
(VI) wherein X is the same linking group mentioned above and R is as defined above, and f) removing the protecting group from the nitrogen atom in the proline ring.
(VII) wherein X is a linking group, which method comprises:
a) treating pyrrolidine with an acylating agent, to yield a protected pyrrolidine of the formula VIII
(VIII) wherein R is C1-6alkyl, C3-6cycloalkyl, benzyl, phenyl, phenyl substituted with one or more C1-6alkyl groups, or trimethylsilylethyl, b) treating the compound of formula VIII with a lithiating agent, to yield a compound of the formula IX
(IX) wherein R is as defined before, c) reacting the compound of formula IX with a trialkyl borate, wherein each alkyl group may be straight, branched or cyclic and may contain l to 6 carbon atoms, and d) hydrolyzing the product of the previous step, to yield a compound of the formula IV
(IV) e) reacting the compound of formula IV with a diol of the formula V, HO-X-OH (V) wherein X is the same linking group mentioned above, to yield a boronate ester of the formula VI
(VI) wherein X is the same linking group mentioned above and R is as defined above, and f) removing the protecting group from the nitrogen atom in the proline ring.
38. The method of claim 37 wherein, in step (c), the intermediate of formula IX is reacted with trimethyl or triethyl borate.
39. The method of claim 37, wherein the linking group X is a saturated 2- to 3-membered hydrocarbon chain; a saturated 2- to 3-membered hydrocarbon chain which constitutes part of a C5-12 carbocyclic system which may optionally contain unsaturations or ring fusions; a 2- to 3-membered hydrocarbon chain which constitutes part of an aromatic ring system; or, X is a group of the formula -(CH2)n-NH-(CH2)m-, wherein n and m are each 2 or 3; wherein such groups may be unsubstituted or substituted by one or more C1-3alkyl or phenyl groups.
40. The method of claim 37 wherein the esterification in step (e) is carried out with a diol selected from the group consisting of ethylene glycol, pinacol, catechol, pinanediol, butan-2,3-diol, diethanolamine, and 1,2-diphenylethan-1,2-diol.
41. The method of claim 40 wherein the diol is optically active pinanediol.
42. The method of claim 41, wherein the N-protected pinanediol ester formed in step (e) of claim 37 is further separated into its diastereoisomers.
43. The method of claim 41, wherein the N-deprotected pinanediol ester formed in step (f) of claim 37 is further separated into its diastereoisomers.
44. The method of claim 37, wherein R is tert-butyl, benzyl, trimethylsilylethyl, phenyl, methyl, or ethyl.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79614891A | 1991-11-22 | 1991-11-22 | |
US07/796,148 | 1991-11-22 | ||
US93619892A | 1992-08-26 | 1992-08-26 | |
US07/936,198 | 1992-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2123128A1 true CA2123128A1 (en) | 1993-05-27 |
Family
ID=27121696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002123128A Abandoned CA2123128A1 (en) | 1991-11-22 | 1992-11-19 | Method for making a prolineboronate ester |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0641347A1 (en) |
JP (1) | JPH07501078A (en) |
CN (1) | CN1073946A (en) |
AU (1) | AU661362B2 (en) |
CA (1) | CA2123128A1 (en) |
CZ (1) | CZ124494A3 (en) |
FI (1) | FI942345A (en) |
HU (1) | HUT67937A (en) |
IL (1) | IL103817A0 (en) |
MX (1) | MX9206628A (en) |
NO (1) | NO941905L (en) |
NZ (1) | NZ245207A (en) |
PT (1) | PT101079A (en) |
SI (1) | SI9200332A (en) |
SK (1) | SK59294A3 (en) |
TW (1) | TW232697B (en) |
WO (1) | WO1993010127A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2116235A1 (en) | 2005-01-10 | 2009-11-11 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US7816364B2 (en) | 2006-04-11 | 2010-10-19 | Arena Pharmaceuticals, Inc. | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto |
US7833730B2 (en) | 2006-04-11 | 2010-11-16 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual |
US7838254B2 (en) | 2008-04-07 | 2010-11-23 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
US5965532A (en) | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
US6100234A (en) * | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
US6040145A (en) | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
DE69837393T2 (en) | 1997-09-29 | 2007-12-06 | Point Therapeutics, Inc., Boston | STIMULATION OF HEMATOPOIETIC CELLS IN THE VITRO |
TWI252107B (en) | 1998-05-04 | 2006-04-01 | Piint Therapeutics Inc | Pharmaceutical compositions and kits for hematopoietic usage |
AU765370B2 (en) * | 1998-06-05 | 2003-09-18 | Point Therapeutics, Inc. | Cyclic boroproline compounds |
US6979697B1 (en) | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
JP2003523396A (en) * | 2000-02-25 | 2003-08-05 | ノボ ノルディスク アクティーゼルスカブ | Inhibition of beta cell degeneration |
WO2003063903A2 (en) * | 2002-02-01 | 2003-08-07 | Probiodrug Ag | Modulation of t lymphocytes using dp iv inhibitors |
SI1689757T1 (en) * | 2003-11-12 | 2015-01-30 | Sino-Med International Alliance, Inc. | Heterocyclic boronic acid compounds |
US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
KR20140089408A (en) | 2003-11-17 | 2014-07-14 | 노파르티스 아게 | Use of dipeptidyl peptidase iv inhibitors |
ES2940341T3 (en) | 2004-01-20 | 2023-05-05 | Novartis Ag | Formulation and direct compression process |
SV2005002092A (en) * | 2004-04-27 | 2005-12-13 | Wyeth Corp | "COUPLING PROCESS FOR THE GENERATION OF PIRROL-2-CARBONITRILE REACTIVE DERIVATIVES N-REPLACED WITH BORO CONTENT TO PRODUCE BIARILOS" REF. AM - 101481 SALVO. |
CA2606785A1 (en) | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
CN1331835C (en) * | 2005-10-18 | 2007-08-15 | 武汉大学 | Preparation method of optically active beta-hydroxy ketone |
AU2006339348B2 (en) | 2005-12-19 | 2013-01-17 | Trustees Of Tufts College | Soft protease inhibitors and pro-soft forms thereof |
SG194349A1 (en) | 2008-06-17 | 2013-11-29 | Millennium Pharm Inc | Boronate ester compounds and pharmaceutical compositions thereof |
US9523687B2 (en) | 2014-02-28 | 2016-12-20 | Institut Pasteur | Levels of CXCL 10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS |
CA2949517A1 (en) | 2014-05-20 | 2015-11-26 | Millennium Pharmaceuticals, Inc. | Boron-containing proteasome inhibitors for use after primary cancer therapy |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
CN108047257B (en) * | 2017-12-17 | 2020-03-13 | 沧州普瑞东方科技有限公司 | Preparation process of chiral N-BOC-pyrrolidine-2-boric acid |
CN110452258B (en) * | 2019-09-03 | 2021-01-01 | 上海馨远医药科技有限公司 | Preparation method of dipeptide valine boron proline salt |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
WO1991016339A1 (en) * | 1990-04-14 | 1991-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type iv |
GB9017694D0 (en) * | 1990-08-13 | 1990-09-26 | Sandoz Ltd | Improvements in or relating to organic chemistry |
-
1992
- 1992-11-18 MX MX9206628A patent/MX9206628A/en unknown
- 1992-11-19 WO PCT/US1992/009845 patent/WO1993010127A1/en not_active Application Discontinuation
- 1992-11-19 HU HU9401350A patent/HUT67937A/en unknown
- 1992-11-19 CA CA002123128A patent/CA2123128A1/en not_active Abandoned
- 1992-11-19 JP JP5509442A patent/JPH07501078A/en active Pending
- 1992-11-19 CZ CZ941244A patent/CZ124494A3/en unknown
- 1992-11-19 PT PT101079A patent/PT101079A/en not_active Application Discontinuation
- 1992-11-19 EP EP92925238A patent/EP0641347A1/en not_active Withdrawn
- 1992-11-19 SI SI19929200332A patent/SI9200332A/en unknown
- 1992-11-19 AU AU31368/93A patent/AU661362B2/en not_active Expired - Fee Related
- 1992-11-19 SK SK592-94A patent/SK59294A3/en unknown
- 1992-11-20 IL IL103817A patent/IL103817A0/en unknown
- 1992-11-20 NZ NZ24520792A patent/NZ245207A/en unknown
- 1992-11-20 TW TW081109304A patent/TW232697B/zh active
- 1992-11-23 CN CN92113215A patent/CN1073946A/en active Pending
-
1994
- 1994-05-20 NO NO941905A patent/NO941905L/en unknown
- 1994-05-20 FI FI942345A patent/FI942345A/en not_active Application Discontinuation
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2116235A1 (en) | 2005-01-10 | 2009-11-11 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US7803754B2 (en) | 2005-01-10 | 2010-09-28 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US7803753B2 (en) | 2005-01-10 | 2010-09-28 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US8198232B2 (en) | 2005-01-10 | 2012-06-12 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US8030270B2 (en) | 2005-01-10 | 2011-10-04 | Arena Pharmaceuticals, Inc. | Methods for identifying GLP-1 secretagogues |
US8022034B2 (en) | 2005-01-10 | 2011-09-20 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US8003597B2 (en) | 2005-01-10 | 2011-08-23 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
EP2253311A2 (en) | 2006-04-11 | 2010-11-24 | Arena Pharmaceuticals, Inc. | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto |
US8101626B2 (en) | 2006-04-11 | 2012-01-24 | Arena Pharmaceuticals, Inc. | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto |
US8017574B2 (en) | 2006-04-11 | 2011-09-13 | Arena Pharmaceuticals, Inc. | Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretagogues |
US8580526B2 (en) | 2006-04-11 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 receptor to identify compounds which stimulate glucose-dependent insulinotropic peptide secretion |
US8026074B2 (en) | 2006-04-11 | 2011-09-27 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual |
US8026212B2 (en) | 2006-04-11 | 2011-09-27 | Arena Pharmaceuticals, Inc. | Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretatgogues |
US7833730B2 (en) | 2006-04-11 | 2010-11-16 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual |
US7816364B2 (en) | 2006-04-11 | 2010-10-19 | Arena Pharmaceuticals, Inc. | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto |
US8486646B2 (en) | 2008-04-07 | 2013-07-16 | Arena Pharmaceuticals, Inc. | Methods of using a G protein-coupled receptor to identify peptide YY (PYY) secretagogues |
US8883714B2 (en) | 2008-04-07 | 2014-11-11 | Arena Pharmaceuticals, Inc. | Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues |
US7838254B2 (en) | 2008-04-07 | 2010-11-23 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10772865B2 (en) | 2015-03-09 | 2020-09-15 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11400072B2 (en) | 2015-03-09 | 2022-08-02 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Also Published As
Publication number | Publication date |
---|---|
CZ124494A3 (en) | 1995-07-12 |
JPH07501078A (en) | 1995-02-02 |
CN1073946A (en) | 1993-07-07 |
AU661362B2 (en) | 1995-07-20 |
TW232697B (en) | 1994-10-21 |
NO941905L (en) | 1994-07-14 |
NZ245207A (en) | 1994-07-26 |
NO941905D0 (en) | 1994-05-20 |
SI9200332A (en) | 1993-06-30 |
MX9206628A (en) | 1993-05-01 |
HU9401350D0 (en) | 1994-08-29 |
WO1993010127A1 (en) | 1993-05-27 |
FI942345A0 (en) | 1994-05-20 |
EP0641347A1 (en) | 1995-03-08 |
HUT67937A (en) | 1995-05-29 |
SK59294A3 (en) | 1995-02-08 |
IL103817A0 (en) | 1993-04-04 |
AU3136893A (en) | 1993-06-15 |
PT101079A (en) | 1994-02-28 |
FI942345A (en) | 1994-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2123128A1 (en) | Method for making a prolineboronate ester | |
CA2121369C (en) | Inhibitors of dipeptidyl-aminopeptidase type iv | |
Snow et al. | Studies on proline boronic acid dipeptide inhibitors of dipeptidyl peptidase IV: identification of a cyclic species containing a BN bond | |
US5462928A (en) | Inhibitors of dipeptidyl-aminopeptidase type IV | |
EP1846424B1 (en) | Proteasome inhibitors and methods of using the same | |
US5384410A (en) | Removal of boronic acid protecting groups by transesterification | |
EP0528858B1 (en) | Inhibitors of dipeptidyl-aminopeptidase type iv | |
US7230074B2 (en) | Inhibitors of dipeptidyl-aminopeptidase type IV | |
ZA200608689B (en) | Synthesis of boronic ester and acid compounds | |
Kelly et al. | The efficient synthesis and simple resolution of a prolineboronate ester suitable for enzyme-inhibition studies | |
EP0724446A1 (en) | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes | |
JP2022068192A (en) | Copper- and nickel-catalyzed decarboxylation reaction | |
AU674067B2 (en) | Enantioselective oxazaborolidine catalysts | |
CA2174311A1 (en) | Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring | |
EP0599633B1 (en) | Boronic ester synthesis | |
Frost et al. | Rhodium catalysed conjugate addition of a chiral alkenyltrifluoroborate salt: the enantioselective synthesis of hermitamides A and B | |
US5543526A (en) | 1-amino-4-(1H-imidazole)- aminobutaneboronic acid derivatives, their preparation and use as synthetic intermediates | |
US7960589B2 (en) | Synthesis of sphingosines and their derivatives | |
Ku et al. | An efficient synthesis of enantiomerically pure unnatural aryl glycinols and aryl glycines | |
US5646287A (en) | Reagents for enantioselective acylation and related reactions | |
Shinada et al. | On the stereoselectivity of asymmetric Strecker synthesis in a cyclohexane system: synthesis of optically active cis-and trans-1-amino-2-hydroxycyclohexane-1-carboxylic acids | |
CN1048485C (en) | Optical active compound and preparing process thereof | |
Drew et al. | Novel peptide isosteres that were designed to inhibit the binding of the HIV surface glycoprotein (gp120) to the T cell surface glycoprotein CD4 | |
Kamisaki et al. | Synthetic studies of salinosporamide A through the intramolecular hydroamidation of alkynes | |
Fabry-Asztalos | Asymmetric synthesis of organoboron compounds bearing peptides and other nitrogen containing substituents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |